Ihmisen mesenkymaalisten kantasolujen erilaistaminen dopaminergisiksi neuroneiksi aivoelektrodimateriaaleilla by Mynttinen, Elsi
Aalto University
School of Electrical Engineering
Degree Program in Bioinformation Technology
Elsi Mynttinen
Differentiation of Human Mesenchymal
Stem Cells into Dopaminergic Neurons
on Brain Electrode Materials
Master’s Thesis
Espoo, May 13th, 2016
Supervisor: Prof. Tomi Laurila
Advisor: D.Sc. (Tech.) Emilia Peltola
Aalto University
School of Electrical Engineering
Degree Program in Bioinformation Technology
ABSTRACT OF
MASTER’S THESIS
Title: Differentiation of Human Mesenchymal Stem Cells into Dopaminergic
Neurons on Brain Electrode Materials
Date: May 13th, 2016 Pages: 9 + 83
Major: Biotronics Code: S3037
Supervisor: Prof. Tomi Laurila
Advisor: D.Sc. (Tech.) Emilia Peltola
Mesenchymal stem cells (MSCs) are multipotent cells that can differentiate into
various cell types depending on their environment, but cannot undergo neuro-
genesis in normal conditions. In contrast, with the appropriate chemical and
mechanical stimuli, these cells can be guided towards the neuronal lineage in
vitro. Moreover, the generated neurons can be further directed into a dopamin-
ergic (DA) subgroup. This process, however, requires optimal growth conditions,
as well as suitable substrates for controlling the cell fate.
In this thesis work, human MSCs (hMSCs) were differentiated into DA neurons
on four different carbon-based materials and the differentiation process with and
without differentiation factors was assessed by following markers related to neu-
rogenesis. The substrate materials were tetrahedral amorphous carbon (ta-C),
ta-C coated with poly-D-lysine (PDL), ta-C coated with carbon nanodiamonds
(vox) and vox functionalized with brain-derived neurotrophic factor (BDNF).
The differentiation medium was a cocktail of BDNF, sonic hedgehog (Shh) and
fibroblast growth factors (FGF2 and FGF8). The expressions of glial fibrillary
acidic protein (GFAP), nestin, neuron-specific enolase (NSE) and thyrosine hy-
droxylase (TH) were tracked by immunofluorescence staining and quantitative
real-time polymerase chain reaction (RT-qPCR).
The results showed the ability of the differentiation medium to induce neuron-like
morphology in the cells cultured for 12 days on all material types. In addition,
the marker profiles revealed a positive effect of the nanostructures on the MSC
differentiation, while PDL coating was found unfavorable for MSCs. Further-
more, the results also indicate that the differentiation process had not been fully
completed by the day 12, implying a need for a longer period in culture.
These experiments demonstrate various challenges related to developing an effi-
cient protocol for DA differentiation from hMSCs, the most important being the
optimization of the combined mechanical and chemical stimuli. Nevertheless, the
use of MSCs holds great promise for therapeutic approaches in several medical
conditions including spinal cord injuries and neurodegenerative disorders such as
Parkinson’s disease.
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Mesenkymaaliset kantasolut (MSC) ovat multipotentteja soluja, jotka voivat eri-
laistua useiksi eri solutyypeiksi ympa¨risto¨sta¨a¨n riippuen, mutta eiva¨t kuitenkaan
normaalisti tuota hermosoluja. Na¨ita¨ kantasoluja voidaan kuitenkin ohjata kohti
hermosolulinjaa in vitro sopivien kemiallisten ja mekaanisten a¨rsykkeiden avulla.
Tuotetut solut voidaan viela¨ erilaistaa tietyksi alaryhma¨ksi, kuten dopaminergi-
siksi neuroneiksi. Ta¨ma¨ prosessi vaatii kuitenkin optimaaliset kasvuolosuhteet,
seka¨ sopivan materiaalialustan erilaistumisen sa¨a¨telemiseksi.
Ta¨ssa¨ tyo¨ssa¨ ihmisen mesenkymaalisia kantasoluja erilaistettiin dopaminergi-
siksi neuroneiksi nelja¨n erilaisen hiilipohjaisen materiaalin pa¨a¨lla¨ ja ta¨ta¨ pro-
sessia seurattiin neurogeneesiin liittyvien merkkiaineiden avulla seka¨ erilaistu-
mismediassa etta¨ ilman erilaistumistekijo¨ita¨. Testatut materiaalit olivat tetra-
hedraalinen amorfinen hiili (ta-C), ta-C pinnotettuna poly-D-lysiinilla¨ (PDL),
ta-C hiilinanotimanttipinnoituksella (vox) ja vox funktionalisoituna BDNF:lla¨
(brain-derived neurotrophic factor). Merkkiaineiden ilmentymista¨ seurattiin im-
munofluoresenssiva¨rja¨yksilla¨ seka¨ kvantitatiivisella real-time polymeraasiketju-
reaktio -menetelma¨lla¨.
Tuloksista na¨htiin, etta¨ materiaalista riippumatta erilaistumismedia sai aikaan
neuronien kaltaista morfologiaa soluissa, joita oli erilaistettu 12 pa¨iva¨n ajan.
Lisa¨ksi havaittiin nanopinnoitteen positiivinen vaikutus kantasolujen erikoistu-
miseen, kun taas PDL-pinnoitus vaikutti epa¨suotuisalta MSC-solujen viljelyyn.
Tuloksista pa¨a¨teltiin myo¨s, etta¨ erilaistumisprosessi saattoi viela¨ olla ka¨ynnissa¨
12 pa¨iva¨n kohdalla. Soluja voisi siksi olla tarpeen erilaistaa pidemma¨n ajanjakson
ajan.
Na¨ma¨ kokeet osoittivat myo¨s useita haasteita liittyen toimivan protokollan ke-
hitta¨miseen MSC-solujen erilaistamiseksi dopaminergisiksi neuroneiksi. Ta¨rkein
na¨ista¨ on sopivien kemiallisten ja mekaanisten stimulusten yhdista¨minen opti-
maaliseksi erilaistumisympa¨risto¨ksi. Tulevaisuudessa na¨ita¨ kantasoluja voitaisiin
ka¨ytta¨a¨ hoitomuotona useissa hermoston sairauksissa, esimerkiksi selka¨rangan
vaurioissa seka¨ hermorappeumasairauksissa kuten Parkinsonin taudissa.
Asiasanat: Ihmisen mesenkymaalinen kantasolu, neurogeneesi, dopami-
nerginen neuroni, tetrahedraalinen amorfinen hiili, hiilinano-
timantti, aivoelektrodi
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1 Introduction
For decades, the prevailing belief throughout the scientific world was that
no new neurons are born in the adult mammalian brain. It was not until
the early 1960s that the discovery of neurogenesis in adult brain was first
reported [1]. This finding soon led to an avalanche of studies confirming
the presence of neural stem cells also in adult human brain as well as their
capability to create new neurons throughout life. As culturing neural stem
cells in vitro became a routine protocol in cell laboratories, it started a whole
new era in the field of neuroregenerative medicine.
The growing understanding of the mechanisms involved in neurogenesis
enabled the development of various methods to differentiate neuronal stem
cells and embryonic stem cells into mature neurons, and later into specific
neuronal cell types. In the year 2000, the next step forward was the successful
stimulation of neurogenesis in mesenchymal stem cells, a subgroup of adult
stem cells that are not capable of neurogenesis in normal conditions [2].
Several years later, human mesenchymal stem cells were further stimulated
into dopaminergic neurons [3]. These milestones have led the path in the
development of stem cell therapies in regenerating the central nervous system.
In several major neurological diseases such as Parkinson’s disease, Hunt-
ington’s disease, multiple sclerosis, spinal cord injury and stroke, the main
pathological course is the destruction of neurons or their structures. The field
of regenerative medicine aims to find solutions to replace the damaged tissue
or assist the tissue in regenerating itself. Stem cells, particularly mesenchy-
mal stem cells (MSCs), have shown strong potential in neuroregeneration as
autologous, non-immunoreactive transplants. The use of stem cells in these
applications has also been combined with stimulative factors [4] and bioma-
terial scaffolds with guiding topographies [5] to provide mechanical support
and promote neural growth and neurogenesis at the injured areas.
Another topic of intense research for the past twenty years has been the
use of electrical stimulation in treating various neurological conditions, es-
pecially Parkinson’s disease [6]. The development of deep brain stimulation
has required designing biocompatible materials with conductive properties
1
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and the ability to support the growth of neural tissue at the implantation
site. In this application, autologous stem cells could be used to further im-
prove the functionality and long-term stability of the electrodes by tailoring
the material-tissue interface. The current challenges include optimizing the
stimulation method of MSCs to generate an active, implantable MSC-coated
brain electrode and guide the stem cells into the neuronal lineage in vivo.
The research areas around this future perspective include gathering more
information of the signaling pathways governing natural neurogenesis, im-
proving the efficiency and specificity of the guided MSC differentiation and
designing suitable materials and differentiation factors for medical purposes.
This thesis is composed of a literature study and a following experimen-
tal part. In the literature review, section 2 gives an overview of the current
level of knowledge on neurogenesis in the adult brain, covering the major
cell signaling pathways in neural and dopaminergic differentiation. Section
3 introduces the different methods used in guiding stem cells into neurons in
vitro, including transfection and chemical and mechanical stimulation. Fi-
nally, the last section of the literature work presents some existing medical
applications of neuroregeneration as well as discusses the possible future di-
rections of the field.
In the experimental part, the first objective is to assess the feasibility of
a differentiation protocol [7] in stimulating human mesenchymal stem cells
into dopaminergic neurons on electrode materials. Therefore, the cells are
cultured and differentiated on four different carbon-based materials that have
potential to be applied in brain electrode applications: tetrahedral amor-
phous carbon (ta-C), ta-C coated with poly-D-lysine (PDL), ta-C coated
with carbon nanodiamonds (vox) and vox functionalized with brain-derived
neurotrophic factor (BDNF).
The ta-C -based substrates have been proven suitable materials for bio-
electrodes and more sensitive towards dopamine than pure platinum [8]. Fur-
thermore, the sensitivity of the electrodes has been further improved by mod-
ifying the layer thickness and by inducing topography to the ta-C surface [9].
In particular, nanoscale structures have been seen to enhance the electrical
properties of the brain electrodes. For example carbon nanotubes lower the
electrode impedance and increase the observed current due to the increased
surface area [10].
Here, the effect of nanotopography is evaluated by coating the ta-C sam-
ples with carbon nanodiamonds. This vox-coating contains multiple carboxyl
groups enabling immobilization of various molecules to the surface. In these
experiments, a growth factor molecule BDNF is functionalized onto the vox
surface to assess the applicability of the carboxyl-linking as well as to inspect
the effects of the immobilized BDNF on the cell behavior. In addition, PDL-
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coating is used as a reference for its known ability to promote cell attachment,
and the suitability of this coating for hMSCs is evaluated.
The purpose of the material experiments is to compare the extent of
the differentiation on all these material types to determine potential con-
ductive or even inducive effects of the coatings and nanostructures on the
dopaminergic differentiation of the cells. In order to do this, the differentia-
tion process is assessed with and without chemical factors by following neu-
ronal markers with immunofluorescence staining and quantitative real-time
polymerase chain reaction (RT-qPCR). The experimental part is comprised
of two parts: section 5 documents the materials and methods used in the
work and section 6 presents the results. In the end, section 7 concludes the
highlights of the literature review and the main results of the experimental
work.
2 Neural differentiation
Since the finding of the regeneration of neurons in mammalian brain in 1962
[1], the research in this area of neuroscience has been growing dramatically.
A specifically interesting subject has been neuronal differentiation in human
brain and its applications in regenerative medicine. To be able to fully take
advantage of the stem cells and their potential in medical applications, it is
essential to first understand the mechanisms and conditions through which
the growth and development of the cells is guided in their natural environ-
ment. Hence, a major part of the research has been focusing on the signaling
mechanisms and factors related to stem cell survival and neurogenesis in the
mammalian and human brain. In this chapter, the main focus is on the
neural stem cells and the cell signaling governing neurogenesis in the adult
brain.
2.1 Stem cells
Stem cells are undifferentiated cells that have the ability to divide and pro-
duce other cell types with specific functions. A stem cell is also able to renew
itself through mitotic cell division. Each division of a stem cell can lead to
either two new stem cells (symmetric division) or one stem cell and one dif-
ferentiated cell (asymmetric division). In mammals, there are two types of
stem cells: embryonic and adult stem cells. Embryonic stem cells (ESCs) can
be found in the inner cell mass of blastocysts, the early stage of the embryo
development, whereas stem cells in adults are located in several tissues, e.g.
blood, bone marrow and adipose tissue.
The differentiation potential, i.e. the potency of a stem cell, can be used
to describe the functionality of different types of stem cells. Totipotent stem
cells are capable of differentiating into any type of cells and a single cell can
divide and differentiate to create a whole organism. The only fully totipo-
tent cells in humans are the ones created during the first few days after
fertilization, including the fertilized egg, until they start to specialize and
4
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become pluripotent. These pluripotent stem cells, which include embryonic
stem cells, can differentiate into all cell types, but cannot produce the entire
organism by itself.
Multipotent stem cells, sometimes also called progenitor cells, have the
potential to develop into multiple but limited cell types. A specific line of
multipotent cells is called mesenchymal stem cells (MSCs), stromal cells that
are found in most human tissues. These cells can differentiate into a variety
of cell types in vivo, including bone, adipose and cartilage cells [11], but are
not able to produce neurons in normal conditions. However, with appropriate
stimuli, MSCs can also be guided into neuronal cells [2].
2.2 Neural stem and progenitor cells
The first evidence of neurogenesis, the regeneration of neurons, in mammalian
brain was observed in 1962 by Altman et al. [1]. Two decades later, this
finding led to the discovery of neural stem cells (NSCs). NSCs were first
found in mammal embryonic central nervous tissue in 1989 [12] and were
later confirmed to also exist in adult human brain [13]. NSCs are multipotent
cells that are capable of differentiating into both neural and glial cells via
intermediary progenitors and thus serve as the source of self-renewal in adult
mammalian brain [14].
The NSCs in the human brain are also called slow proliferating cells or
type B cells [15], and they give rise to type C cells, fast-proliferating transit-
amplifying progenitor cells [15, 16]. These neural progenitors then generate
either proliferating neuroblasts (type A cells), or glioblasts. Neuroblasts are
dividing progenitor cells committed to the neuronal fate and further dif-
ferentiate into neurons, whereas glioblasts generate non-neuronal glial cells,
including astrocytes and oligodendrocytes [17] (see Figure 2.1).
NSCs are constantly generated in two parts of the brains of adult humans:
the dentate gyrus (DG) of hippocampus and the subventricular zone (SVZ)
of the lateral ventricles (LV) [13] (see Figure 2.2). SVZ is a remnant of
the embryonic germinal neuroepithelium, and is the part of the forebrain,
in which the NSCs are most abundant [19]. In human hippocampus, the
neurogenesis takes place in the subgranular zone of the dentate gyrus, from
which the generated neurons migrate into the granule cell layer [13].
In contrast to other mammals, there seems to be no detectable migration
to or active neurogenesis in the olfactory bulb of the adult human brain [20].
The NSCs in the SVZ differentiate into neuroblasts, which then in the non-
human mammalian brain migrate to the olfactory bulb through a structure
called the rostral migratory stream [21]. On the contrary, in the human brain
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Figure 2.1: Differentiation of neural stem cells. Neural stem cells (type B)
have the ability of both self-renewal and differentiation into all neuronal sub-
types, e.g. astrocytes, oligodendrocytes and neurons, through intermediary
progenitor cells (type A and type C).
Figure 2.2: The adult human neurogenic system. The subventricular zone
(SVZ; indicated by the arrow) is located between the lateral ventricle (LV)
and the striatum (Str.). The hippocampal dentate gyrus (DG) lies near the
center of the brain. (Modified from [18])
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the destination of the migrating neuroblasts seems to be mainly the striatum
of the brain, in which they differentiate into interneurons [22] (see Figure
2.2). However, the debate over whether a rostral migratory stream exists in
human brain is still ongoing [22, 23].
2.3 Cell signaling during adult neural differ-
entiation
The process of neurogenesis in the adult brain is tightly regulated and guided
by a wide variety of cellular signaling pathways. Understanding these mecha-
nisms underlying the behavior of the neural stem and progenitor cells during
maturation and differentiation is the key to recreating the optimal growth
environment for these cells outside the body. The knowledge of the intrinsic
signaling is also a useful tool for tracking the progress of differentiation in in
vitro conditions. The major pathways activated during adult neurogenesis
are Wnt - beta-catenin, sonic hedgehog and notch, accompanied by an array
of growth factors and neurotrophic factors (see Figure 2.3).
2.3.1 Notch pathway
The maintenance of adult NSCs is regulated through Notch pathway. Ac-
tivation of a Notch receptor by ligand binding promotes cell cycle exit and
progenitor differentiation, thus decreasing the pool of neural progenitors [24].
The Notch signaling is mediated through an intracellular signal mediator,
RBPj (Recombination signal binding protein for immunoglobulin kappa J
region) [25]. RBPj in turn acts as a transcriptional activator inducing the
expression of transcription factors, such as a neurogenesis associated gene
Hes1 (Hairy enhancer of split) [25, 26]. RBPj has been shown to exist both
in adult SVZ [27] as well as the hippocampus [28].
Two of the receptors involved in the adult brain are Notch1 and Notch3.
In the adult hippocampus, Notch1 is found to be required for NSC differen-
tiation into progenitor cells both in vivo and in vitro [29], while activation
of Notch3 seems to result in maintaining quiescence of the stem cells [30].
Furthermore, inactivation of RBPj induces an initial increase in neurogene-
sis by promoting neural differentiation, resulting in a subsequent depletion
of the stem cell pool and a substantial decrease in neurogenesis [27, 28]. In
the light of these findings, it seems clear that the Notch pathway indeed has
an important role in regulating the maintenance of adult NSCs.
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Figure 2.3: Neural differentiation and proliferation signaling in adult brain.
The promoting factors are indicated with black arrows and the inhibitors
with orange ones with end caps. The curved arrows represent the induction
of self-renewal and maintenance.
2.3.2 Wnt signaling pathway
Wnt pathway has been shown to be involved in various different processes
in the adult brain, including neuroblast proliferation, neuronal differentia-
tion and development of dopaminergic (DA) neurons. Wnt signaling in the
so called canonical Wnt pathway operates through a signal transducer pro-
tein, beta-catenin. In the absence of Wnt, beta-catenin is phosphorylated
and degradated, resulting in a low intracellular beta-catenin level [31]. The
degradation of beta-catenin prevents subsequent transcription of Wnt target
genes, whereas a high level of beta-catenin allows initiation of Wnt-target
gene transcription.
In adult hippocampus, Wnt signaling has been shown to regulate neu-
roblast proliferation and neuronal differentiation via beta-catenin [32]. A
member of the canonical Wnt pathway, Wnt1, is especially associated with
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the differentiation of neurons, and it is an important promotor of DA differ-
entiation [33, 34]. In addition to Wnt1, Wnt3 also induces neurogenesis both
in vivo and in vitro, and its inhibition results in reduced neurogenesis in adult
hippocampus in vivo [32]. Two other signaling proteins, Wnt5a and Wnt7a
together with Wnt3a, participate in the proliferation, self-renewal and differ-
entiation of NSCs. Wnt7a is mostly studied in the adult hippocampus [35],
while Wnt3a and Wnt5a have been found active in the SVZ neural progenitor
cells in vitro [36].
2.3.3 Sonic hedgehog pathway
Sonic hedgehog (Shh) is an extracellular signaling protein, which regulates
the proliferation of the neural progenitor cells in both adult hippocampus
[37] and SVZ [38]. The Shh pathway includes two receptors, a transmem-
brane receptor protein Patched (Ptc), and its G protein-coupled co-receptor
Smoothened (Smo) [39]. In the absence of an Shh ligand, Ptc receptor in-
hibits signal transduction from Smo, thus preventing the transcription of Shh
target genes. In contrast, binding of an Shh ligand to Ptc enables the ac-
tivation of Smo-regulated signaling cascade, which leads to transcription of
Gli-dependent and other Shh target genes.
The receptors Ptc and Smo have been found to be expressed in both
adult hippocampus [40] and the subventricular zone [38]. Overexpression of
Shh increases the proliferation and the number of progenitor cells in vitro
[41] and in vivo [37, 42], whereas blocking the pathway has been shown to
have the opposite effect. Similarly, direct inhibition or dysfunction of Smo
receptor has been found to result in significant reduction in progenitor cell
proliferation in the postnatal hippocampus and SVZ [38] as well as in adult
hippocampal dentate gyrus in vivo [43].
2.3.4 Growth factors and neurotrophic factors
Growth factors, a large family of extracellular signaling proteins, constitute
to the neuronal development by promoting cell proliferation and supporting
maintenance [31]. Important growth factors involved in adult neurogene-
sis include bone morphogenetic proteins (BMPs), insulin-like growth factor
(IGF), fibroblast growth factor 2 (FGF2, also called basic fibroblast growth
factor bFGF) and vascular endothelial growth factor (VEGF). These growth
factors bind to receptors belonging to the tyrosine kinase family, which in-
duces the activation of their specific downstream signaling pathways.
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Bone morphogenetic proteins
Bone morphogenetic proteins are a group of extracellular signaling molecules
that form the widest subgroup of the transforming growth factor-beta (TGF-
β) superfamily [31]. BMPs have a multifunctional role in both embryonic and
adult nervous systems affecting a variety of cellular processes including cell
survival, proliferation and fate specification. In the embryonic brain, BMPs
seem to be required for initializing stem cell proliferation and neurogenesis,
while in the adult brain they function to promote quiescence of NSCs to
prevent stem cell exhaustion [44].
The activity of BMPs is mediated by BMP receptors I and II. Upon BMP
ligand binding, these receptors cooperate to set in motion an intracellular
signaling cascade involving inhibitory Smad proteins, which in turn initiates
the transcription of target proteins [45]. In the adult SVZ, BMPs serve as
inhibitors for neuronal differentiation, while in the striatum it is suggested to
direct differentiation towards the astroglial fate [46, 47]. BMPs are expressed
in the subventricular zone by neural stem and progenitor cells, in which they
prevent the differentiation of these type B and C cells into neurons.
One of the most important BMP inhibitors is Noggin, which is a protein
produced by ependymal cells in the central nervous system [46]. Noggin an-
tagonizes BMP signaling, thus promoting NSC proliferation and increasing
neurogenesis in the adult hippocampus both in vivo and in vitro [46, 48].
Blocking BMP signaling by Noggin seems to result in initial increase in neu-
rogenesis in adult DG, but a subsequent loss of precursors and neurogenesis,
suggesting that BMPs are indispensable for maintaining neural stem cells
and regulating neurogenesis [44].
Insulin-like growth factor
Insulin-like growth factor type 1 (IGF-1), a growth-promoting peptide hor-
mone, is endogenously produced in adult neural progenitors in SVZ and is
required for spontaneous neurogenesis [49]. In the adult hippocampus, IGF-1
has also been seen to directly stimulate neural progenitor cell proliferation
in vitro together with FGF2 [50] as well as increase the rate of neurogenesis
in vivo [51]. In addition to cooperating with FGF2, IGF-1 also seems to
function as an instructive signaling molecule for the BMP pathway [52]. The
inhibition of BMP signaling by IGF-1 seems to induce the differentiation of
adult hippocampal progenitor cells and direct them into oligodendrocytes
and neurons at the expense of the astroglial fate.
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Fibroblast growth factor 2
FGF2 is another growth factor connected to adult neurogenesis and it has
been found to affect especially hippocampal neurons. In the aging adult
brain, the diminishing proliferation rate and dendtritic growth of neurons
has been connected to a decrease in the levels of FGF2, alongside with IGF
and VEGF [53]. The same effect has also been observed in FGF-receptor
deficient mice, which show significant decrease in neural progenitor prolifer-
ation accompanied with reduced production of new neurons in the adult DG
[54]. Inversely, the infusion of FGF2 into the adult brain results in addition
of new neurons in the hippocampal DG, which indicates an important role
of FGF2 in maintaining the self-renewal of neurons [55].
Vascular endothelial growth factor
VEGF has originally been known for its function as a promoter for vascular
endothelial cell proliferation, but is also suggested to be involved in various
processes in both developing and adult nervous system. This multifunctional
growth factor seems to affect several different neuronal activities including
neuronal growth and maturation during development [56] as well as hip-
pocampal lesion-induced reorganization [57]. Furthermore, VEGF seems to
act as both neurotrophic and neuroprotective factor in adult neurogenesis.
The receptors for VEGF signaling are expressed on both endothelial and
neuronal progenitor cells in adult hippocampus and SVZ [58]. VEGF acts
directly via these receptors as a mitogenic factor for neuronal progenitor cells
[59]. It has also been shown that direct infusion of VEGF into the lateral
ventricle of adult rat brain promotes neurogenesis in both SVZ and SGZ [59].
Brain derived neurotrophic factor
Neurotrophins comprise a small group of proteins with various functions
acting primarily on cells of the nervous system [60]. In mammals, four neu-
rotrophic factors have been identified: nerve growth factor (NGF), brain-
derived neurotrophic factor (BDNF), neurotrophin 3 and neurotrophin 4/5.
Among these four, the brain-derived neurotrophic factor (BDNF) is the most
extensively studied. The multiple roles of BDNF in the central nervous sys-
tem include involvement in progenitor maturation and survival, neuronal
development, differentiation and synapse formation and axonal regeneration
[61].
BDNF acts through binding to a receptor tyrosine kinase abbreviated as
TrkB receptor. This receptor is expressed on dividing progenitor cells both
in the adult SVZ [62] as well as in the neurogenic zone of the hippocampal
DG in mouse [63]. In contrast, while BDNF has also been reported to be
expressed in the adult hippocampus, there is no evidence of BDNF activity
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in the SVZ. In fact, it has recently been suggested that BDNF would not
have a stimulative role in SVZ neurogenesis [64].
Despite the substantial amount of research done on BDNF function, its
regulation and connections to other pathways has long remained unclear.
Only recently have some studies started to link the activity of BDNF sig-
naling to that of the Wnt/β-catenin pathway. In glial cells, BDNF seems
to be a direct target of Wnt signaling [65], whereas in human neurons the
roles of these two appear to interchange [66]. These studies imply a complex
relationship between the BDNF and Wnt pathways - a crosstalk regulating
the growth and development of human neurons.
2.3.5 Neurotransmitters
Neurotransmitters predominantly operate as the basis of chemical signaling
between neuronal synapses. However, recent studies have also implicated a
coexisting role for neurotransmitters in the regulation of adult neural progen-
itor cell proliferation, differentiation and adult neurogenesis [31]. The main
effective neurotransmitters are glutamate, dopamine and GABA (gamma
aminobutyric acid).
The evidence of glutamate intervention in neurogenesis is only an emerg-
ing subject for research, but it has been addressed by studying the expression
of glutamate receptors on neural cells. In the adult hippocampus SVZ, the
glutamate receptor NMDA (N-methyl-D-aspartate) seems to govern a regu-
latory role on neurogenesis [67].
GABA functions as the main inhibitory neurotransmitter in the adult
brain. The most essential GABA receptor involved in neurogenesis is the
GABAA receptor, which is activated during neurogenesis in the adult SVZ
[68]. GABA is secreted by differentiating neuroblasts and bound to GABAA
receptors on neural stem cells. The receptor activation then results in inhi-
bition of NSC proliferation, thus providing a feedback mechanism regulating
NSC proliferation. Furthermore, GABA has also been found to stimulate hip-
pocampal newborn neurons in the adult brain, prominently improving their
dendritic development and synaptic integration into the existing neuronal
network [69].
Dopamine is a catecholamine regulating a vast range of functions in the
adult brain. Similarly to glutamate, also the studies on dopamine as a neu-
rotrophin have focused on dopamine receptor expression. The two types of
dopamine receptors are D1-like (D1 and D5) and D2-like (D2, D3 and D4),
divided by their structural and functional similarities [70]. In the adult SVZ,
the D2-like receptors are especially expressed on transient amplifying cells
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(type C), which are targets for hippocampal DA signaling. Loss of this sig-
naling for example due to DA denervation leads to a significant reduction in
the proliferation rate of the type C precursor cells in the SVZ [71, 72].
2.4 Signaling pathways in dopaminergic dif-
ferentiation
Dopamine is a neurotransmitter secreted mostly by the DA neurons of the
midbrain [73]. The loss of DA neurons in the midbrain structure called sub-
stantia nigra is the main cause of Parkinson’s disease, a neurodegenerative
disease affecting several neurological functions. The differentiation process
of these neurons involves, for the major part, the same pathways that are
active in neurogenesis. However, the later stages of the differentiation re-
quire specific signaling that guides the cells towards mature DA cells. These
signaling factors, including Shh, Wnt, FGF8, notch and BDNF, act in a time
dependent manner to regulate the development of the cells. The major sig-
naling pathways are summarized in Figure 2.4. Studying the generation of
DA neurons in vivo has enabled the first attempts to create these specific
neurons in vitro, giving hope to future applications in regenerative medicine
for example for Parkinson patients.
2.4.1 Sonic hedgehog
In addition to its role in the regular neurogenesis, Shh is also involved in
the process of DA neuron development (see Fig. 2.5). In mammalian ven-
tral midbrain (VM), Shh induces the expression of the homeodomain factor
Lmx1a (LIM homeobox transcription factor 1 alpha), which subsequently
induces the expression of its downstream effector, transcription factor Msx1
(Msh homeobox 1) [74]. Msx1 in turn initiates the expression of a proneu-
ronal gene Ngn2 (neurogenin 2), thus supporting neuronal differentiation in
DA neurogenesis.
The overexpression of Lmx1a in the VM results in generation of DA neu-
rons, while reduced expression results in a loss of neurons with DA function
[74]. A related factor, Lmx1b, has been shown to cooperate with Lmx1a in
mediating the DA fate of neural precursors [75]. Similar to Lmx1a, overex-
pression of Lmx1b can also increase the production of DA neurons in VM
[76] and conversely, reduce the number of DA neurons when depleted in VM
[75].
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Figure 2.4: A summary of the major signaling factors and pathways regu-
lating neuronal growth, differentiation and proliferation in the adult brain.
The promoting factors are indicated with black arrows and the inhibitors
with orange ones. The curved arrows represent the induction of self-renewal
and maintenance. The differentiation stimulants used in the experiments of
this work are highlighted in bold.
In addition to Shh, another transcription factor, Otx2 (Orthodenticle
homeobox 2), is required for the expression of Lmx1a. Otx2 has been shown
to regulate Ngn2 expression [77] by inducing the expression of Lmx1a [78]. In
the absence of Otx2, neural precursors in VM fail to activate the expression
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of Lmx1a, Msx1 and Ngn2, and consequently fail to differentiate into DA
neurons [79].
Lmx1a expression is also modulated by FoxA2, a transcription factor
part of a feedback loop with Shh [80]. Shh signaling is known to regulate
Gli2 activator molecule, which in turn upregulates the expression of Gli1,
an effector of Shh pathway [81]. Gli1 then induces the expression of FoxA2
[82], subsequently modulating Lmx1a expression. On the other hand, FoxA2
has also been suggested to regulate Shh expression [83], which implicates a
possible feedback loop between Shh and FoxA2. The loss of either Gli1 or
Gli2 in vivo has shown to result in reduction of DA neurogenesis [84].
Figure 2.5: Shh signaling in adult DA neurogenesis. Shh promotes neuronal
differentiation via various downstream effectors. The inducive pathways are
indicated with arrows.
2.4.2 Wnt in dopaminergic neurogenesis
There seems to be a connection between the Wnt pathway and the devel-
opment of DA neurons. The inactivation of Wnt1 and Wnt5a proteins have
been associated with a loss of DA neurons in the adult midbrain [85]. In ad-
dition, it has been shown in vitro, that Wnt3a and Wnt5a might cooperate to
induce neurogenesis by Wnt3a mediated progenitor proliferation and Wnt5a
induced differentiation of NSCs.
Wnt1 seems to act as a key regulator of the proliferation and differen-
tiation of VM DA progenitors into DA neurons both in vitro [33] and in
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vivo [34]. Another Wnt protein, Wnt2, has also been implicated as a regu-
lator of DA differentiation, since the absence of Wnt2 results in suppressed
DA neurogenesis [86]. Furthermore, Wnt3a has been shown to induce DA
progenitor proliferation but to inhibit their differentiation, whereas Wnt5a
specifically enhances differentiation of progenitors into DA neurons [33, 87].
Conclusively, several signaling molecules of the Wnt family seem to have an
essential role in regulating both maintenance and differentiation of the DA
progenitors.
2.4.3 Sonic hedgehog and Wnt cooperation
Recent results have suggested a possible link between Shh and Wnt signaling
in the regulation of DA neurogenesis (see Fig.2.6). It has been proposed,
that Wnt is required to antagonise Shh, and the suppressed Shh levels allow
the differentiation of VM progenitors into DA neurons [88]. This finding is
not in an agreement with the previously stated results, which have shown the
important role of Shh in inducing DA neurogenesis. It is possible, however,
that Shh is initially required to create the VM DA progenitor pool by induc-
ing neurogenesis, but is later involved in inhibiting their proliferation and
differentiation. This theory suggests that once the Shh-induced progenitor
pool has been established during development, Wnt signaling reduces Shh
levels in VM, enabling DA neurogenesis.
Wnt has also been shown to promote Otx2 and Lmx1 expression [34, 88],
both of which are known to participate in inducing neurogenesis. An autoreg-
ulatory loop between Wnt1 and Lmx1a has been proposed to control Otx2
expression via β-catenin during VM DA neurogenesis [89]. More recent data
also shows that Lmx1a and Lmx1b might function cooperatively to regulate
the proliferation of DA progenitors through modulating Wnt1 expression [90].
In addition, Otx2 has also been found to regulate Wnt1 expression therefore
affecting DA neurogenesis [79], suggesting a Otx2-Wnt1 regulatory feedback
loop involving both Lmx1a and Lmx1b.
It is still being investigated, whether the Wnt1-Lmx1a and the Shh-FoxA2
autoregulatory loops control VM DA neurogenesis synergistically [89], or
whether the interaction between Wnt and Shh pathways is indeed antago-
nistic [88, 91]. However, taking these studies together it is evident that Wnt
signaling is required for DA neurogenesis, involving a complicated coopera-
tion with Shh as well as other signaling factors.
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Figure 2.6: The interaction between Wnt and Shh signaling in adult DA
neurogenesis. Wnt1 is linked to the Shh pathway via Lmx1 expression, and
establishes a Wnt1-Otx2 regulatory loop that controls DA differentiation.
The inducive pathways are indicated with arrows, while the dotted one with
an end cap represents a suggested inhibitory regulation of Shh by Wnt1.
2.4.4 Notch in dopaminergic neurogenesis
Since Notch has been found to be the key regulator of the maintenance of
NSCs, it is not surprising that it has also seen to affect DA differentiation.
Studied in fruit flies, DA neurons were observed to differentiate only from
cells without active Notch signaling [92]. This indicates that Notch signaling
would function as a suppressor of DA neurogenesis. The Notch pathway is
included in Figure 2.7.
One mediator in the Notch-induced repression of neurogenesis has been
shown to be the downstream effector Hes1, a transcription factor inhibiting
DA differentiation [93]. The involvement of Hes1 has been confirmed by
studying its activator, Nato3. The transcription factor Nato3 was found to
promote neurogenesis by repressing Hes1 expression. Nato3, on the other
hand, acts downstream of FoxA2, thus suggesting a link between the Shh,
Wnt and Notch pathways.
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2.4.5 Neurotrophins and growth factors
In addition to their substantial role in neurogenesis, growth factors and neu-
rotrophic factors also participate in the regulation of DA differentiation. The
most important factors are FGF2, fibroblast growth factor 8 (FGF8) and
BDNF. The contribution of these factors to DA neurogenesis is presented in
Figure 2.7.
Fibroblast growth factors
FGF8 is another member of the fibroblast growth factor family, belonging
to the same group of proteins with FGF2. FGF8 is required to induce the
correct patterning of VM DA progenitors [94]. The loss of FGF receptors has
been seen to result in altered patterning of the VM and failure of VM DA
neuron maturation. FGF2, on the other hand has been shown to regulate DA
progenitor proliferation, as well as the developmental cell death of mature
DA neurons [95].
FGF8 has been suggested to have a connection with both Wnt and Shh
pathways. Wnt1 is an essential regulator of the expression of two engrailed
genes, En1 and En2 (Homeobox protein engrailed-1 and -2) [96]. The absence
of these genes in mice generate a DA neuron depleted ventral midbrain similar
to Wnt1-deficient mice [97] and thus are believed to be required to prevent
apoptosis in DA neurons [98]. Apart from Wnt1, FGF8 has also been shown
to regulate En1 expression in the developing VM [94], presumably through
Wnt1. Since Wnt-β-catenin signaling has already been shown to upregulate
FGF8 expression [99], an autoregulation loop similar to that of Shh and
FoxA2, might also exist between Wnt and FGF8.
While Gli1 and Gli2 are shown to connect Shh to FoxA2, another tran-
scription factor of the Gli family, Gli3, is involved in the Shh signaling. Gli3
functions as a repressor, and is suppressed by Shh to allow the de-repression
of FGF8 expression [81]. In other words, by antagonising Gli3, Shh induces
FGF8 expression and therefore facilitates DA neurogenesis. It has also been
demonstrated in vitro, that the combination of Shh and FGF8 signaling
molecules on NSCs results in the most effective induction of DA neurons
[100].
Brain-derived neurotrophic factor
BDNF has been seen to support the survival of neurons in the adult fore-
brain [101] as well as the survival of DA neurons in the substantia nigra in
vitro [102]. Subsequently, BDNF has also been demonstrated to be able to
induce maturation of hMSCs into DA neurons and increase the DA release
upon stimulation [103]. In addition, BDNF seems to have an inducive role in
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neurogenesis in vivo, in neurons originating from both adult dentate gyrus
[102] and SVZ [104, 105]. It might be even probable that BDNF is required
for the survival of DA neurons in specific parts of the brain [106].
Figure 2.7: The major pathways and signaling factors affecting DA differen-
tiation in adult brain - Wnt, Shh, FGF8 and Notch. Notch functions as an
antagonist for DA neurogenesis, while FGF8 cooperates with both Wnt and
Shh pathways to induce neurogenesis. The inducive pathways are indicated
with arrows, while the ones with end caps represent inhibitory effects.
There is still a lot of research to be done in order to completely map
the factors and pathways related to neurogenesis and DA differentiation.
The signaling mechanisms directing stem and progenitor cells to differentiate
into neurons also partly overlap with those of generating glial cells. This is
especially seen during the embryonic development [107], but is also evident in
the adult brain, as can be deduced from the multiple studies reviewed above.
Another challenge regarding the research on cell signaling pathways is the
fact that a major part of the experiments are conducted using rodent cells or
other non-human models. Therefore, attention has to paid to the possibility
that these results obtained from other organisms might not be analogous to
the human nervous system [108].
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In summary, the cellular signaling in the central nervous system com-
prises of a highly complex network of growth factors and morphogens, which
are secreted in a time-dependent manner and controlled by intracellular,
extracellular and environmental factors. This section presented the main
chemical factors governing neurogenesis and DA differentiation in the adult
brain according to the current literature (summarized in Fig. 2.4). While
all of these factors have been demonstrated to have a role in the process of
adult neurogenesis in vivo, it has been shown that the fate of stem cells in
in vitro conditions can be affected already by a few of them, if applied into
the cell culture at correct dosages. Currently, various mixtures of differenti-
ation factors can be used to produce neural-like cells, and in this work, four
different stimulants (highlighted in bold in Fig. 2.4) were chosen to induce
DA differentiation in MSCs.
3 Guided neurogenesis
Guiding the differentiation of stem cells, especially MSCs, into neurons is a
relatively new area of research in the field of neuroscience. The first demon-
strations of guided neurogenesis from MSCs have been published in the be-
ginning of the 21st century [2]. Starting with rodent stem cells and followed
by numerous studies on human MSCs, these studies have introduced MSCs as
a possible tool for regenerative medicine in neurological diseases. In guiding
neuronal differentiation, the methods used today include chemical stimula-
tion, transfection of pivotal genes and culturing on substrates designed to
enhance neurogenesis.
3.1 Chemical stimulation
In chemical stimulation, a range of growth factors and neurotrophic factors
have been used in differentiating stem cells into neural cells. Currently,
BDNF, retinoic acid (RA) and FGF2 are among the most prevalent factors
used in guiding MSC differentiation into neurons. For further inducing the
cell fate towards DA neurons, the frequently used growth factors include Shh,
FGF2 and FGF8, BDNF and ascorbic acid. The role of these molecules in
the differentiation process is discussed in the previous section (see Section 2)
and are summarized in Figure 2.4. Inducing neurogenesis in MSCs has been
studied using several different media cocktails with varying combinations of
growth factors.
In generating neurons from MSCs, BDNF, a member of the nerve growth
factor (NGF) family, has been identified as a trophic factor for neuronal cells
in the midbrain in vitro [102]. For its known ability to promote neurogenesis,
BDNF has been used as a differentiation factor in several protocols aiming
to increase neuronal and/or DA differentiation in stem cells [103, 109–111].
In addition to BDNF, RA is often used as a part of the induction medium
for its known role in neural development [112]. In the early studies with adult
stem cells, RA was seen to promote neural differentiation in both mouse and
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human bone marrow MSCs [113]. Together with epidermal growth factor
(EGF) in the proliferation medium, BDNF and RA were found successfully
differentiate these cells into a neuronal lineage.
Although providing initial evidence of the capacity of stromal cells to
differentiate into neurons, the first experiments resulted in significantly low
yields. As the research on guided neurogenesis has evolved, the efficiency of
the differentiation protocols has increased. Some of the differentiation factors
contributing to the higher yields were FGF2 and FGF8, which together with
EGF and BDNF were seen to be able to stimulate approximately 70% of
hMSCs into neuron-like cells [112].
FGF2 and FGF8 are frequently used in guiding DA differentiation, along
with Shh and ascorbic acid. The important role of Shh as a possible inducer
of DA differentiation in vitro was first established by Hynes et al. [114].
Later on, the combination of Shh and FGF8 was demonstrated to increase
the differentiation of both mouse and human embryonic stem cells into DA
neurons in vitro [115], in which the role of FGF8 is though to be to promote
midbrain specification [116]. Additionally, the co-effect of Shh and FGF8
together with FGF2 also results in a significant increase in DA differentiation
in human ESCs [116].
Recently, studies with human bone marrow derived MSCs have further
confirmed the important roles of Shh, FGF2 and FGF8 in DA neurogenesis
[117]. These signaling molecules efficiently promote differentiation of MSCs
into DA neurons both separately as well as in different combinations. Adding
ascorbic acid to a mixture of Shh and FGF8 has also been used to induce DA
differentiation in stem cells in vitro [118]. Furthermore, the addition of EGF
and FGF2 into a differentiation protocol including FGF8, Shh and ascorbic
acid, has been proven to further facilitate neuronal fate and differentiation
of ESCs into DA neurons [119].
3.2 Transfection
Transfection is a technique that modifies the genetic expression of a cell by
altering the nucleic acid sequence. The change in the genomic code results for
example in overexpression of the corresponding protein. While traditionally
used mainly in examining and studying neurogenesis, transfection has now
been employed as an active tool in differentiating stem cells into neurons.
The transcription factors studied as stimulative agents include Nurr1, Pitx3,
Lmx1, En1/En2 and Ascl1.
Nurr1 (nuclear receptor related 1 protein) is a transcription factor that
was shown to be related to neurogenesis in midbrain DA neurons already in
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1997 [120]. A year later, the role of Nurr1 was specified to be involved in
the later states of the differentiation process into DA neurons, the lack of
Nurr1 leading to impaired DA specification and subsequent degeneration of
the precursor cells [121].
When overexpressed in mouse NSCs, Nurr1 was seen to induce the ma-
jority of the cells to adapt a neuron-like morphology [100]. Moreover, the
addition of Shh and FGF8 into the Nurr1-transfected cell culture induced DA
differentiation, while this was not observed in control cells without transfec-
tion. These results were significant, since the cell line used in the experiments
is not normally able to give rise to DA neurons in vitro.
The Nurr1-mediated guiding of differentiation towards DA neurons has
been suggested to function through cooperation with another transcription
factor, Pitx3 (pituitary homeobox 3) [122]. Pitx3 alone seems to be required,
but not sufficient, for the development of DA neurons in the substantia ni-
gra, since mice lacking this protein failed to develop these specified neurons
[123]. In contrast, the co-transduction of Pitx3 with Nurr1 successfully pro-
motes the maturation of DA neurons from both mouse and human ESCs
[122]. This combination resulted in significantly increased levels of a terminal
maturation DA marker DAT (dopamine transporter) as well as reduced the
expression of non-neuronal markers. While this Nurr1/Pitx3 co-stimulation
profile showed promising results in vitro, it was proven unsuitable for in
vivo-implementation as such. The co-transduced ESCs were grafted into le-
sioned adult mice in the progenitor cell stage, but they showed only low TH
expression, indicating a demand for additional inductive factors for in vivo
applications.
A recent study assessed the transfection potential of another homeodomain
protein, Lmx1 [74]. Lmx1a and Lmx1b are known targets for neurogenic Shh
signaling (see section 2.4), and hence raised interest in direct use as stim-
ulative factors. It was indeed shown that Lmx1a was both required and
sufficient to trigger the process of DA differentiation in mouse ESCs. The
cells were transfected with Lmx1a and cultured in a differentiation medium
consisting of FGF2, FGF8 and Shh. The protein Lmx1b, on the other hand,
introduces an independent pathway regulating midbrain DA differentiation
[75]. The lack of Lmx1b production inhibited the induction and expression
of Pitx3 leading to the death of specified midbrain DA neurons, whereas the
expression of Nurr1 was not compromised.
In addition to the above mentioned homeodomain proteins Pitx3 and
Lmx1, the fate of midbrain DA neurons is also controlled by two home-
odomain transcription factors En1 and En2 [97]. These two engrailed genes
(see section 2.4) are expressed by midbrain DA neurons throughout their life,
controlling the survival of these neurons rather than affecting their differen-
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tiation. In mice lacking these genes, the neurons are generated normally and
differentiated into DA phenotypes, but then disappear in short time. While
the absence of En2 alone results in nearly normal DA neuron distribution in
the midbrain, the lack of En1 has a substantial degenerative effect leading to
apoptosis of the majority of the DA neurons. For their role in maintenance of
the generated DA neurons, En1 and En2 could have potential as transfection
factors, but are yet to be implemented in this area.
Another type of transcription factor, Ascl1 (Achaete-scute homolog 1),
has been linked to the cellular commitment of NSCs in both embryonic and
adult brain [31]. In contrast to the genetic factors contributing to promoting
neurogenesis, Ascl1 has been shown to induce adult hippocampal progenitor
cells into oligodendrocytes instead of neurons [124]. In the adult brain, Ascl1
is shown to be transiently expressed by progenitor cells that subsequently dif-
ferentiate into either oligodendrocytes or neurons [125]. However, the over-
expression of this transcription factor instructed the cells to take up another
pathway at the expense of their usual commitment towards glutamatergic
neurons [124]. As this experiment demonstrates, it is not always particularly
straightforward to predict the outcome of experiments when modifying the
intricate machinery of the cells.
The challenges related to transfection-based stimulating strategies are
mostly related to the complex nature of all cellular processes. The generation
of new neurons and the specification into a certain subtype involves tightly
controlled extracellular signaling as well as stage-specific gene expression pro-
grams. Hence, it is not likely that a single transcription factor could govern
the complex process of neuronal and DA differentiation. On the contrary,
it seems evident that a rather complicated combination of transcriptional
factors have to be activated to complete the task.
3.3 Mechanical stimulation
Despite the positive results obtained from transfecting specific genes into
cell cultures and animal models, this method might not be the most opti-
mal one for clinical practice. As discussed above, it is not a simple matter
to predict all the cumulative effects of the engineered genes on other in-
terrelated pathways. In addition, the challenge of targeting the right cell
population in a patient sets another obstacle for implementing this method
in practice. Consequently, more effort has been put on taking advantage of
inherent stimulants to correct neural dysfunction. While using soluble pro-
teins and molecules to induce neuronal growth and differentiation has been
a subject for intense research for the last decades, the success in therapeutic
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applications has yet to be accomplished. This is mainly due to various prob-
lems related to solubility, stability, concentration and spatial and temporal
positioning of the factors [126].
A potential strategy to overcome these limitations could be the use of
suitable biomaterials to support the process. A growing interest has emerged
towards taking advantage of mechanical factors and the properties of the
substrate materials in order to affect cell behavior. Accumulating evidence
shows the effects of both static and dynamic mechanical cues in guiding
neuronal growth and neurogenesis. The possibilities in material modulation
include chemical modification, topographic micropatterning and nanoscale
surface featuring.
3.3.1 Material properties and chemical modification
Several material properties and modifications contribute to the cell behavior
and can be utilized to promote neurogenesis. Favorable properties of the
material itself include low stiffness, good biocompatibility and applicability
of modifications, the most frequently used materials being different types
of polymers and carbon substrates. The surface of the substrate can be
modified for example by lithographic methods to create micropatterns or
chemical modifications to promote neural growth and differentiation.
One of the underlying substrate properties contributing to the cell behav-
ior is the stiffness of the material. Since the natural environment of the neural
cells consists of the relatively soft extracellular matrix, it seems only logical
that stem cells would prefer differentiating into neuronal lineages on softer
surfaces rather than stiffer ones. Indeed, a variety of studies have shown that
when MSCs are cultured on deformable substrates (E ∼ 0.1-1 kPa), such as
soft gels, they tend to differentiate toward neuronal phenotype [127, 128],
while stiffer matrices induce myogenesis (∼ 11 kPa) and osteogenesis (∼ 34
kPa) [127]. Compliant materials also specifically favor neuronal growth over
that of glial cells [129].
Static micropatterning can also be combined with dynamic mechanical
stimulation, such as stretching of the substrate, to create mechanical tension
to the cells. To study the effects of both parallel and vertical tension, guiding
microchannels were generated on elastic polydimethylsiloxane (PDMS) sub-
strate and rat neuronal stem cells were cultured on the material [130]. The
substrate was stretched repeatedly over several days and the effects were
assessed by following neurite growth, axon elongation and differentiation be-
havior. The cells experiencing parallel tension were observed to express en-
hanced neurite and axonal outgrowth and orientation as well as promoted
differentiation and maturation into neuronal cells.
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Chemical modification is still another approach established for enhancing
biomaterial properties. Graphene has been proposed as a biomaterial for
neural interfacing, and its properties for stimulating neurogenesis have been
enhanced by chemical processing. Graphene itself has excellent biocompat-
ibility properties and it stimulates neurite growth of hippocampal neurons
in vitro [131]. In addition, fluorinated graphene has been shown to facili-
tate hMSC fate toward neuronal lineage, making it a promising substrate
for stimulating stem cells [132]. Furthermore, this carbon-based material has
unusual electrical conductivity, and it can be fabricated into thin, flexible
and highly transparent films, which could have great potential as a material
for implantable nervous system applications.
3.3.2 Micropatterning
In the micrometer scale, stem cells can be guided by different patterns and
pattern sizes. The width as well as the depth of the micropatterns has been
seen to affect both the differentiation rate [133] and selective differentiation
of stem cells [134]. With patterns too narrow and deep, the cells are highly
constrained and cell-cell connections impaired, leading to smaller differenti-
ation rates and decreased neurite development [133]. On the contrary, for
wider micropatterns with a width larger than that of the soma (usually ∼13
μm), the differentiation rate and neurite growth of the cultured adult human
NCSs increased and were comparable with flat, unpatterned surfaces. Simi-
larly, no difference was observed in the differentiation rate of adult rat neural
progenitor cells into neurons when cultured on micropatterns with a width
of 16 μm [134].
These observations were also consistent with results from human MSC
differentiation on both micro- and nanogratings [135]. Gratings with widths
10 μm, 1 μm and 350 nm were generated on a polymer substrate, and the
results showed that while hMSCs were able to differentiate into neuronal
lineages on all feature sizes, the effect was bigger on the nanoscale patterns.
This is suggested to be due to the unconstrained environment, in which the
neurites are free to spread and grow in multiple directions. The differentiation
processes is hindered by a decrease in the number of neurites in the cell, and
the neurites in turn seem to require a certain amount of physical space to
protrude from the soma.
In addition to the size of the patterns, also the shape of the micropattern
contributes to the stimulating effect of the substrate. This was addressed in
a study comparing culturing of adult NSCs on linear, circular and dotted mi-
cropatterns, with feature sizes 2 μm and 10 μm [136]. The linear and circular
patterns with both feature sizes were observed to promote NSC differentia-
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tion towards neuronal lineage mainly by depressing astrocytic differentiation.
Furthermore, the neuronal differentiation was allowed to a greater extent on
the smaller patterns compared to the larger ones.
These studies suggest that the pattern itself would determine the differ-
entiation fate, while the feature size affects the extent of the differentiation
[136]. In the current literature, a vast array of different micro- and nanos-
tructures, such as channels, grafts, grooves and dots have been examined in
inducing differentiation of stem cells. Despite of the great amount of research,
the detailed mechanisms governing the effect of the substrate topography on
the cell behavior remain unclear. However, it is assumed that these mecha-
nisms include the initial cell adhesion and spreading, the resulting geometry
and orientation of the cells and consequent changes in gene expression leading
to altered proliferation and differentiation.
3.3.3 Nanotopography
While both micro and nanometer features and topographies have been shown
to promote cellular growth and differentiation of neurons, the effect of nano-
materials has proven even more substantial. This is likely due to the bio-
mimicry of the nanostructures, which resemble the nanoscale features of the
natural growth environment of the cells [137]. The contacts between the
neurons and their environment rely on adhesion sites, so called focal adhe-
sions, that are established via integrins [138]. These interactions occur in the
5-200 nm range and thus are greatly affected by nanotopographic features
[138, 139].
Since nanomaterials are able to both favour neuronal adhesion as well as
offer a natural-like microenvironment, they are a promising group of materials
for promoting neuronal growth, directing neurogenesis and designing neural
tissue scaffolds and transplants for medical applications. The frequently used
materials to generate nanofeatures are polymers and carbon nanotubes and -
fibers. By electrospinning, several polymer materials have been fabricated to
create nanoscale surface features. These polymers include poly-L-lactic acid
(PLLA), polycaprolactone (PCL) polyurethane and polyethersulfone (PES).
To increase the biocompatibility of the materials, the polymers have also been
coated with natural polymers such as collagen and laminin. For applications
requiring electric conductivity, conductive polymers have been employed as
differentiation substrates.
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Polymer-based nanostructures
Several studies have shown the applicability of electrospun PLLA nanoscale
fibers for neural tissue engineering and stem cell differentiation. Especially
aligned PLLA fibers efficiently direct neural growth while also supporting
NSC differentiation into neurons [140]. When co-polymerized with caprolac-
tone and blended with collagen (PLCL/Coll), PLLA has also been shown to
promote neurogenesis in hMSCs [141]. The addition of the natural collagen
into the PLCL co-polymer further increases the biocompatibility of PLCL
while also improving its mechanical properties favorable for nerve regenera-
tion applications.
Caprolactone itself has also been fabricated into poly(ε-caprolactone)
biodegradable fiber scaffolds to induce mouse ESCs [142] as well as adult
rat NSCs [143] to differentiate towards the neuronal lineage. In both studies,
the stem cells were seeded onto electrospun PCL fibers and stimulated with
retinoic acid with surprisingly similar results. The cells were seen to gener-
ate all types of neural cells, including astrocytes, oligodendrocytes and early
neurons. A comparison between aligned and randomly distributed nanofibers
revealed the capability of the aligned scaffold to both guide the neurite out-
growth as well as discourage differentiation into astrocytes and oligodendro-
cytes. Both of these aspects would be important properties for a scaffold
used for example to repair nerve injuries and to promote neuronal survival.
An even more recent approach to polymer-based scaffolds in neuronal re-
generation is a possibility for controlled drug release from the biomaterial
substrates. For example nerve growth factor (NGF) and retinoic acid have
been added into PCL-scaffolds to further enhance its stimulative properties.
To add NGF to a stem cell substrate, PCL was first co-polymerized with
poly(ethylene glycol) to generate amine-functionalized block co-polymers [144].
This material was electrospun into nanofibrous meshes and then conjugated
with NGF. When rat MSCs were cultured on the nanofibers, NGF was re-
leased from the matrix and found to clearly enhance neurogenesis. In a simi-
lar manner, also the encapsulation of RA within aligned PCL-fibers resulted
in increased expression of neural markers in human MSCs [145].
Polyurethane and PES are also biocompatible polymers used in electro-
spinning to generate fibrous scaffolds. Human embryonic stem cells (hESC)
grown on polyurethane fibers cultured with bFGF and EGF expressed posi-
tive neuronal markers after up to 47 days in culture [146]. The most interest-
ing observation was done when comparing the positive markers seen from cells
on the fiber scaffold and on a control substrate omitting the fibers. Although
having otherwise identical differentiation condition, the lack of nanofibers in-
duced the hESCs to preferentially differentiate towards glial cells, while the
cells grown on the fiber substrate showed positive staining for both mature
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neuronal as well as DA neuronal markers.
Similarly to polyurethane, also PES fibers coated with laminin promoted
neuronal differentiation of adult rat NSCs when cultured with RA [147]. In
this experiment, the diameter of the fibers was found to significantly affect
the behavior of the cells. While polymer fibers with a diameter of 283 nm
increased NSC differentiation into oligodendrocytes, fibers with 749 and 1452
nm drove elongation of the neurites along a single fiber axis and consequently
promoted differentiation into neurons. In consensus with these results, also
nanopillars fabricated from PDMS were observed to enhance the rate of neu-
ral differentiation by the increased pillar size from 35 to 400 nm [148].
As can be seen from these experiments, it is challenging to find the opti-
mal parameters for the fabricated nanofibers and the optimal differentiation
factors to chemically stimulate neurogenesis. Furthermore, while polymer
materials have been proven to provide a biomimetic environment for main-
taining survival of stem cells and promoting neurogenesis, most of them are
still not suitable for a substantial amount of applications due to their lack of
electrical conductivity. This shortage, however, could be overcome by using
conductive polymers, a subgroup of organic polymers with metallic or semi-
conductive properties.
Conductive polymers
Several types of conductive polymers, such as polypyrrole (PPy) [149], polyani-
line (PANi) [150] and poly(3,4-dioxyethylenethiophene) (PEDOT) [149, 151]
have been fabricated into nanofiber-based coatings for neural tissue inter-
faces. All of these polymers have shown good electrical properties as well as
capability to support neural adhesion and growth on the substrate surface.
However, since these materials are fairly new in the field of biomaterials,
some issues still need to be addressed in order to generate safe and efficient
coatings for implantable devices.
While PANi has the advantage of an easy synthesis and low costs, the
use of this polymer in biological applications is limited by its lack of flexi-
bility and biodegradability, poor processibility and the evidence showing a
chronic inflammation following implantation [152]. In contrast, PPy is easily
modified to possess suitable properties, including larger surface areas, differ-
ent porosities and excellent biocompatibility. However, it is very difficult to
further process once synthesized, and is also mechanically rigid and brittle,
non-thermoplastic and insoluble.
To date, PEDOT has shown the greatest promise in neural electrode ap-
plications due to the possibility of modifications as well as good electrical,
chemical and environmental stability. [152]. An interesting application of
PEDOT was demonstrated in an electrode interfaced with neural tissue by
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in situ polymerization of PEDOT [153]. Once implanted, PEDOT formed
filaments long enough to extend away from the electrode, bypass possible
fibrous scar tissue and make contact with the healthy neurons around it.
However, even PEDOT is not an entirely optimal material, facing some of
the mutual obstacles among conducting polymers related to complicated pro-
cessing and biocompatibility optimization.
In addition to biocompatibility issues, another major challenge related to
conducting polymers is the stability of the deposited polymer layers. The
problem of delamination has been observed to be an issue for both PEDOT
and PPy -coatings as films but not as nanofiber structures [149]. While fab-
rication into nanostructures improves the adherence of the coating, it raises
another concern about the effects of possible nanoparticle leakage into the
surrounding environment. As long as the toxicity of nanoparticles is still un-
der investigation, these materials are not allowed to be used in implantable
medical applications.
Carbon nanotubes and -fibers
Carbon nanotubes (CNTs) are cylindrical nanostructures generated from
graphene sheets wrapped onto themselves [154]. In neuroscience applications,
the mostly used geometries are single-walled carbon nanotubes (SWCNT)
and multi-walled carbon nanotubes (MWCNT). SWCNTs are made up of a
single graphene sheet closed at its ends by fullerene caps, whereas MWCNTs
are comprised of several concentric graphene cylinders. In addition to their
high conductivity, these carbon nanotubes also exhibit excellent mechanical
strength and supposedly good biocompatibility.
One of the first experiments on carbon nanotubes as a substrate for
stem cells studied culturing NSCs on SWCNT assembled with layer-by-layer
poly(ethyleneimine) (PEI) thin films [155]. This piloting study confirmed
the ability of carbon SWCNTs to support the differentiation of NSCs in the
presence of a suitable differentiation medium. Since then, SWCNT-based
scaffolds have emerged as effective tools not only to maintain, but also to
promote stem cell and progenitor fate towards the desired neuronal lineage.
Human ESCs were first successfully differentiated into neuronal progeni-
tors and neurons on CNT-derived matrices [156, 157]. In these experiments,
CNTs were observed to direct the stem cell fate towards the neuronal lin-
eage while having no negative effects on the cell viability. Furthermore, the
mesh like surfaces seemed to enhance protein adsorption and cell attachment,
whereas there were no apparent cytotoxic reactions from the cells [157].
Later, various studies showed the effect of SWCNT and MWCNT mate-
rials in guiding hMSCs towards neurogenesis [158–160]. Both SWCNTs [158]
and MWCNTs [160] have been seen to upregulate neuronal markers from
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hMSCs when cultured on the nanosubstrates without any agitation by an
exogenous induction medium. Also MWCNTs fabricated into aligned sheet-
like orientation directed hMSC morphogenesis and axon outgrowth inducing
differentiation into neural cells under the influence of a neurogenic medium
[159]. Recently, the trend in the neuroregeneration field has been shifting
from these 2D nanosubstrates towards fabricating 3D matrices to best mimic
the natural growth environment of the neural stem cells. One approach to
generate 3D substrates is a hydrogel-based structure encapsulating CNTs,
shown to present a non-toxic, neurogenic environment for MSCs [161].
The non-toxicity of the novel CNT-based substrates is not a matter of
course, which is why so much effort is being put on finding solutions to shield
the environment from possible nanoparticle leakages. As discussed previously
with polymer-based nanostructured materials, the toxicity of these substrates
is still debatable. So far, there has been no conclusive evidence of the toxicity,
degradation and safety of carbon nanotubes [162]. However, it has been
suggested that appropriate functionalization and route of administration can
make carbon nanotubes both biodegradable and biocompatible.
In contrast to stem cells differentiated into neurons by chemical stimu-
lation, there is currently no evidence of the electrophysiological function of
the neurons generated by carbon-based topographical stimulation [5]. The
expression of specific neuronal markers is a good indication of the desired
direction of cell maturation, but is not a sufficient implication of electrically
functional neurons. Thus, the next important step in utilizing nanomaterials
in neuroregenerative applications would be the assessment of the functional-
ity of the acquired neurons. Another challenge in this area is the synaptic
integration of the new neurons into the existing neuronal network. Since
nanoscale features evidently are able to guide axon and neurite outgrowth,
they could provide an answer to this problem of complexity.
From this vast variety of experiments, it is difficult to conclude which fea-
tures sizes, patterns or topographical cues would comprise the most effective
way to stimulate stem cell differentiation. The main reason for this is the
wide variance of material features, fabrication methods and coatings some-
times combined with a mix of differentiation factors, that are employed in
directing the behavior of the cells. There would be a demand for more coher-
ent and comprehensive series of studies that would address the effects of the
material features and chemical factors separately in order to find the optimal
cues for guiding stem cell differentiation into functional neurons. However,
it seems that the combination of nanotopography and a mix of chemical cues
could have the most favourable effect on cell behavior, providing that issues
such as nanoparticle toxicity and stability of the soluble factors could be
overcome.
4 Medical applications
Neurological dysfunctions such as stroke, traumatic brain injury, spinal cord
injury, and a variety of neurodegenerative diseases are an enormous health
issue world wide, and a lot of effort has been put into solving the problem
of regeneration and functional restoration of the damaged central nervous
system. Neural tissue engineering is an area of this research field, studying
different biomaterials and their suitability to repair or support the injured
neural tissue. Many types of materials can be fabricated to affect the survival,
differentiation and functional activities of stem cells and neurons. These
studies are also the basis for implementing the biomaterials into stem cell
therapies, clinical application that aim to restore the damaged tissue by
implanting stem cells and directing their growth and differentiation into the
desired cellular lineages.
4.1 Regenerative neural tissue engineering
The area of tissue engineering in the central nervous system faces multiple
challenges related to issues such as biocompatibility, stability and function-
ality of the implanted structures. Ideally, a repair system should be able to
support regrowth of injured axons and possibly stimulate the generation of
new neurons and their differentiation as well as promote their integration into
the existing neuronal network [5]. In practice, these requirements establish
a need for appropriate agents and structures to overcome the unfavorable
and most often inhibitory environment for axonal regrowth, organization,
synaptic remodeling and cell survival and differentiation.
4.1.1 Supporting scaffolds for neural interface
One of the pitfalls of the neuroregenerative research has been the limitations
related to two dimensional cell cultures. While being suitable platforms for
exploring the effects of various signaling factors and surface topographies,
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the 2D structures lack the potential for real life in vivo applications. A three
dimensional growth environment is essential for assessing the growth and
behavior of neural tissue in a natural-like setup. Especially the formation
of functional synaptic networks and electrophysiological function fail to be
completed in 2D cell cultures [163]. Thus, there is a demand for more complex
culture and transplant scaffolds for repairing neural tissue damage.
Although the field of 3D fabrication is a fairly new area of material sci-
ence, several polymer-based scaffolds have already been designed for neural
interface applications. A particularly useful method for designing 3D cultures
employs the material group of hydrogels. These polymer-based materials of-
fer both a solid support as well as an aqueous dispersion medium for neurons
and stem cells [164]. In general, hydrogels have a low elastic modulus that
can be further modified to simulate the stiffness of the neural tissue. These
materials can also be tuned to improve their biocompatibility and degrada-
tion rate, which makes them a favorable choice for neural tissue constructs.
In addition, hydrogel-based 3D implants enable mass transfer conditions sim-
ilar to those of the natural tissue, which could help the cells to better adapt
for implantation [163].
Modification of the hydrogel structures can also be used to further control
the growth conditions of the cultured cells. The addition of nanotubes and
-fibers into the hydrogel has been shown to serve as a guidance matrix for
neuron growth and neurite extension [165]. The 3D hyaluronic acid hydrogel
scaffold was integrated with aligned laminin-coated PCL-nanofibers. This
combination material allowed directional control over the neurites, a property
that could prove useful in engineered neural tissue applications.
Culturing stem cells on 3D hydrogel structures has already shown promise
of enabling the type of cell behavior that has not been previously possible
with 2D culture conditions. A recent study demonstrated the formation
of neuroanatomical structures on an organoid culture system, on which the
stem cells exhibited capability to self-assemble and to model human cortical
development [166]. This approach could also be used as a tool for disease
models, as it would allow creating specific dysfunctions in an environment
accurately mimicking the human brain.
Although the 3D constructs have shown great promise in in vitro condi-
tions, it is difficult to predict how they will perform in the inhibiting in vivo
environment of the central nervous system [163]. However, the achievements
in this field have already opened new possibilities for neural regeneration.
The use of combination hydrogel scaffolds would enable embedding different
signaling factors and nanoscale guiding systems to influence cell attachment,
survival, differentiation and neurite extension. In addition, the embedding
of nanostructures into a hydrogel matrix could be used to reduce the risk
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of leaking of the nanoparticles into the surrounding tissues. The most effec-
tive grafts for neural regeneration would probably include both structural,
scaffold-mediated cues as well as integrated stimulation factors.
In the future, it might be even possible to recreate some of the complex
neuroanatomical structures, such as the cortex or spinal cord [163]. For
example, the multilayered cortex could be formed by guiding the cell growth
with layered nanofibers, so that the upper layers would promote intracortical
connections and the lower layers direct the cell extension to develop into deep
projections. This could be achieved by using induced pluripotent stem cells
(iPS cells) or even MSCs, which would enable designing autologous cell grafts
to replace damaged brain areas.
4.1.2 Stem cell therapies
The applicability of ESCs, iPS cells as well as MSCs has been assessed in
multiple studies during the past twenty years. However, MSCs have recently
been of particular interest in stem cell therapies for their multipotency and
possibility to create autologous transplants with no rejection issues. In con-
trast to using embryonic cells for research, the use of MSCs does not involve
any questionable ethical issues. In addition, the process of generating these
cells is less complex and thus less expensive than that of iPS cells. The strat-
egy of the stem cell therapy may be either differentiating stem cells in vitro
into the desired cell lineage and subsequent transplantation into the affected
region [167], or direct transplantation of the stem cells followed by in vivo
differentiation [168]. The potential of different stem cell therapies have been
studied in a variety of neurodegenerative diseases and brain injuries, such as
ischemic brain damage, multiple sclerosis and Parkinson’s and Huntington’s
disease.
One of the first applications of stem cell therapy has been the restoration
of lost neurons in ischemic brain injury [169]. Ischemia is the condition in
which the blood flow to the brain is disturbed as a result of a blockage or a
hemorrhage. Thus the aim of the stem cell therapy in this context would be
the replacement of the dead cells at the site of the injury. The effectiveness
of stem cells has been assessed with multiple animal models using embryonic
[170], neuronal [171] or mesenchymal stem cells [172–174]. In addition, a
recent study showed an enhanced recovery in ischemic stroke patients after
an injection of autologous MSCs [175]. While successful transplantation has
been achieved with all of these different cell types, a great deal of effort is
still required for the optimal clinical outcome [169].
Multiple sclerosis (MS) is a neurodegenerative, chronic autoimmune dis-
ease described by inflammation and deterioration of the myelin sheath of
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motor neurons [176]. The clinical trials during the past few years have been
focusing on ensuring the safety of the transplantation of stem cells into MS
patients [177, 178]. The injection of MSCs into patients unresponsive to tra-
ditional medication has resulted in a decrease in characteristic lesions [178]
and has also shown potential neuroprotective and regenerative effects [177].
Despite of these encouraging results, the capability of MSCs to differentiate
into all types of neuronal cells in vivo is yet to be proven [177]. However,
the transplantation procedure itself has been shown to be feasible as well as
relatively safe [177, 178] with no serious adverse effects observed.
The stem cell treatments for Huntington’s disease (HD) are still in ani-
mal testing, but have nevertheless shown promising effects in these disease
models. HD is a progressive neurodegenerative disease characterized by de-
generation of the striatum, with disabling and essentially fatal clinical course
[179]. One pathological mechanism related to the neuron loss seems to be the
dysfunction of astrocytic secretion of neurotrophic factors. Therefore, these
NTFs, for example BDNF and GDNF, have been directly delivered into the
affected sites to increase neuronal survival [180, 181]. As the transplantation
of autologous MSCs had previously been proven to reduce the neurologi-
cal symptoms of HD [182], a new strategy was soon developed to combine
these two factors to create NTF-secreting stem cells [179, 183]. These studies
confirmed the improved clinical performance of the engineered MSCs com-
pared to native ones, thus establishing a new possible therapeutic approach
to treating MS.
The search for stem cell therapies in Parkinson’s disease has been on-
going for more than a decade, starting from animal models and proceeding
into clinical trials in human patients during the past few years. In two dif-
ferent studies, ES cells were used to produce DA neurons via two different
approaches. In the other experiment, DA neurons were derived from ES
cells and transplanted into a mouse disease model [167], while the other one
first transplanted the ES cells, followed by differentiation in vivo [168]. In
both studies, the generated DA neurons showed correct functionality at the
transplantation site.
ES cells were shown to be capable of spontaneous DA differentiation and
to possess potential for implementation in clinical applications. However, the
high potency of the ES cells comes at a price, as these cells have also been seen
to form tumors after transplantation in vivo [168]. Thus, the use of ES cells
is never straightforward, which is why the option of MSCs has become more
favorable in generating DA neurons. MSCs have shown neuroprotective and
anti-inflammatory effects both in vitro and in vivo [184, 185]. In addition,
clinical trials conducted using bone marrow -derived autologous MSCs in PD
patients have shown promising evidence of the effects of the treatment on the
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condition of the patients [186]. Similarly to the engineered stem cells hoped
to treat HD, new NTF-secreting cells are also designed to be transplanted to
patients with Parkinson’s disease in the new future [187].
Various trials in stem cell therapies have given hope for clinical implanta-
tion in untreatable neurological diseases. However, several hurdles are still to
be overcome in the way to successful and safe stem cell transplantation into
human patients. One challenge is to find the correct timing for the injection
[169]. In animal studies, the stem cell injection is usually given directly after
the disease model is generated, while this is not practical in clinical situa-
tions. Other issues requiring further research include the dosage to be used
as well as the need of repeated dosages, the route of administration and pos-
sible use of scaffolds or other delivery structures. The fundamental challenge
is to find a way to control the development of the stem cells in order to avoid
tumor formation, while simultaneously create a functional subset of neurons
with the ability to fire action potential and integrate into the existing neural
network.
4.2 Conductive interfaces for neural stimula-
tion
Brain electrodes have been developed for chronic stimulation in various neu-
rological diseases including Parkinson’s and Alzheimer’s disease as well as
sever depression and chronic pain. In these applications, both carbon nan-
otubes and polymer-based nanostructures have been shown to improve the
performance of the electrode in in vitro and in vivo applications [149, 188].
Due to their higher surface area, the nanofibers lower the electrode impedance
and increase the observed current [10, 151]. The long-term functionality is
also enhanced by nanotubes designed to support neurite outgrowth and at-
tachment to the electrode surface [149].
Although the implantable electrodes have already been applied to clinical
practice [6], there are still some difficult issues especially related to the host
response of the neural tissue [189]. The inflammation reaction results in a
glial scar formation replacing the neuronal cells around the implanted elec-
trode, leading to encapsulation and loss of function. This event also greatly
reduces the number of neurons in the close vicinity of the electrode.
One approach to improve the biocompatibility of the electrode has been
to determine the optimal mechanical properties for the material. A lot of
research has focused on finding the most suitable physical dimensions and
stiffness for the implantable device [190]. It seems that the size of the elec-
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trode itself should be minimized, but should still exhibit high conductivity
and moderate softness to mitigate the host tissue response.
Another strategy to reduce the inflammation effect of the implantation
would be to tailor the material to actively guide neuronal growth and mi-
gration towards the electrode surface [188]. This could be achieved by for
example using nanostructures together with integrated soluble factors to
guide neurite growth or by introducing stem cells or progenitor cells at the
implantation site to generate new neurons directly at the surface. If the
differentiation of DA neurons from MSCs could be made more efficient and
reliable enough, there could be a clinical window for this method to be im-
plemented in simultaneous regeneration of the affected neural network and
restoring the dopamine levels in the midbrain.
While the first clinically applied brain stimulation electrodes have proven
successful, the research is still ongoing to further optimize the performance
and meet the needs of the patients. An example of such an improvement is
the concept of closed-loop neurostimulation [191, 192]. While the traditional
device delivers stimulation at constant parameters, the closed-loop system
would allow adaptation to the disease condition by simultaneously monitoring
certain biological markers. For example in PD, responsive stimulation could
reduce the fluctuations of the symptoms as well as increase the battery life,
thus requiring fewer replacement procedures [192]. To become a reality, such
applications need optimized material properties and surface structures as well
as highly biocompatible electrodes to be able to both sense and stimulate the
surrounding neurons.
5 Materials and methods
In this thesis work, the aim was to differentiate hMSCs into DA neurons on
different brain electrode materials. Several experiments were conducted to
modulate the protocol of Trzaska et al. [7] in order to succeed in differentiat-
ing hMSCs, as well as compare the effects of different electrode materials on
the differentiation process. The first pilot experiments were done by growing
C6, PC12 and hMSCs on glass coverslips to test the differentiation protocol,
antibodies for immunofluorescence and quantitative PCR (qPCR) principles.
In the main experiment, four different carbon-based materials were tested as
a substrate for hMSC differentiation. The methods used to assess the cell
differentiation were immunofluorescence staining and real-time quantitative
PCR. A process diagram for the experiments is presented in Figure 5.1.
5.1 Sample preparation
The pilot experiments were conducted using glass coverslips (Menzel Gla¨ser
12 mm, Thermo Fisher Scientific) as a growth substrate for C6, PC12 and
hMSC cells. In the electrode material experiments, the carbon materials used
for hMSCs were silicon substrates coated with tetrahedral amorphous car-
bon (ta-C), ta-C coated with poly-D-lysine (PDL), ta-C coated with carbon
nanodiamonds (abbreviated as vox) and vox functionalized with BDNF. All
of these material types were tested with and without chemical stimulation
(see Table 5.1).
The sample size was 1 cm x 1 cm for all material samples. The ta-C
samples were prepared by first depositing a 20 nm Ti layer onto a conducting
silicon wafer by magnetron sputtering, followed by a 7 nm ta-C film fabricated
by filtered cathodic vacuum arc (FCVA) [8]. The nanodiamond-coating was
then produced by a spraying technique, further described in the paper by
Elomaa et al. [193]. The nanodiamond solution (5 wt-% in water) was
diluted in ethanol 1:100 to prepare a solution with 0.05 wt-%. The spraying
was done from a distance of 10 cm and the scanning was repeated ten times,
the pressure being 3.5 bars.
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Table 5.1: Different materials and coatings used in the electrode material
experiments. The materials were tetrahedral amorphous carbon (ta-C), ta-C
coated with PDL, ta-C coated with carbon nanodiamonds (vox) and vox
functionalized with BDNF. All sample types were tested with and without
chemical stimulation.
Material Coating Stimulation
ta-C No No
No Yes
PDL No
PDL Yes
ta-C + vox No No
No Yes
BDNF No
BDNF Yes
PDL-coating was used in all glass coverslip experiments as well as some
of the material experiments to enhance the attachment of the cells onto
the surface. All material samples were first sterilized in 80% ethanol for
15 minutes, after which the ethanol was removed and the samples washed
with PBS (phosphate-buffered saline, VWR). 2 ml of poly-D-lysine hydrobro-
mide (Sigma) was diluted in 38 ml serum-free medium (Dulbecco’s Modified
Eagle’s Medium, DMEM). 0.7 ml of this solution was pipetted into the 24-
well plate wells and 1.4 ml into the 12-well plate wells and the plates were
coated for 1 h at room temperature (RT). The PDL was then aspirated and
the wells were washed with PBS.
BDNF-protein was linked to the sample surface by an enzyme linkage sys-
tem using a zero-length EDC-NHS crosslinker (1-ethyl-3-(3-dimethylamino-
propyl)carbodiimide hydrochloride, N-hydroxysuccinimide, Sigma). 300 μl
of a EDC-NHS solution (0.2 M/0.05 M) was incubated on the correspond-
ing samples for 2 h at RT. The samples were washed with PBS, and BDNF
(brain-derived neurotrophic factor, human, Sigma) diluted in di-water (50
ng/ml) was added and the samples were incubated for 1 h at RT.
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5.2 Growing cells on samples
The cells used in these experiments were stored at -196◦C at passages between
3 and 5 and cultured on Petri dishes with 10 cm of diameter (Corning Inc.,
New York, NY, USA). The C6-cells from a rat glial cell line (ATCC R© CCL-
107TM, Manassas, VA, USA) were used to assess the feasibility of the GFAP
antibody (see section 5.4). The cells were subcultured once (medium F-
12 HAM Nut Mix (Sigma) supplemented with 15% horse serum (HS, Bio-
west), 2.5% fetal bovine serum (FBS, GibcoTM Thermo Fisher Scientific), 1%
Penicillin Streptomycin (Thermo Fisher Scientific) before using them in the
experiments. At approximately 70-80% confluence, the cells were detached
using 2.5 mg/ml trypsin in PBS-EDTA (0.01 ml/cm2) at RT for 5 min. They
were then suspended in culture medium and transferred into three 24-well
plate wells with coverslips coated with PDL (cell density 5.3 x 105/cm2). The
cells were allowed to adhere overnight at 37◦C and 5% CO2 before staining.
PC12-cells (ATCC R© CRL-1721.1TM, Manassas, VA, USA) derived from
the rat embryonic neural crest were cultured to test nestin, NSE and TH anti-
bodies in addition to GFAP (see section 5.4). The cells were subcultured once
(medium F-12K Nut Mix (GibcoTM Thermo Fisher Scientific) supplemented
with 15% HS, 2.5% FBS, 1% PS) and at approximately 70-80% confluence
detached from the dishes by scraping. The cells were suspended in new
medium and transferred into nine wells of a 24-well plate with PDL-coated
coverslips (cell density 2.2 x 104/cm2) and incubated overnight.
The differentiation protocol and the assessment methods using antibodies
and qPCR were also tested on hMSCs cultured on PDL-coated glass cover-
slips before applying them to the material samples. Human bone marrow
derived MSCs (PoieticsTM, Lonza, Walkersville, MD, USA) were thawed
and cultured on Petri dishes with 10 ml of Lonza Mesenchymal Stem Cell
Growth Medium, (MSCGMTM) containing Mesenchymal Stem Cell Basal
Medium (MSCBMTM) supplemented with Mesenchymal Stem Cell Growth
Supplement, L-glutamine and GA-1000 (Gentamicin/Amphotericin-B).
The obtained cells were subcultured once, allowed to proliferate for ap-
proximately 7 days and then detached using 0.25% trypsin in PBS-EDTA
(0.035 ml/cm2) at RT for 8-10 min. An equal volume of temperature equili-
brated MSCGM was added, the suspension was transferred to a Falcon tube
and the trypsin was removed by centrifuging at 600 × g for 5 min. The
cells were then resuspended in MSCGM and seeded onto the well plates (cell
density 5.0 x 103/cm2). For each three time points (see section 5.4), two
replicates for each antibody were prepared into four 24-well plates. Each
plate also contained a negative control sample. In addition, three replicates
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per time point were assembled into one 12-well plate (without coverslips) for
qPCR.
For the material experiments, hMSCs were obtained as described above.
For each three time points (see section 5.4), the hMSC cells were transferred
onto four 24-well plates containing nine samples of each material type, two
replicates for each antibody plus negative control. The cells were seeded onto
a total of 216 samples (12 well plates) with the density of 5.0 x 103/cm2 and
incubated overnight.
5.3 Differentiation protocol
The differentiation of the hMSCs was conducted following the guidelines of
the protocol of Trzaska et al. [7]. After the overnight incubation, the medium
of the corresponding samples was changed to a differentiation medium con-
sisting of 0.4 ml/0.82 ml Neurobasal Medium (GibcoTM Thermo Fisher Sci-
entific), 0.8 μl/1.6 μl B27 Supplement (0.5%, GibcoTM Thermo Fisher Sci-
entific), 2 μl/4.1 μl Shh (250 ng/ml, Sigma), 1.6 μl/3.3 μl FGF8 (100 ng/ml,
Sigma) and 0.8 μl/1.6 μl FGF2 (50 ng/ml, Sigma) for the 24-well plate wells
and 12-well plate wells respectively.
The wells were placed back into the incubator at 37 ◦C and 5% CO2
and incubated for 9 days. At the 9 day time point, 0.2 μl/0.4 μl (24-well
plate and 12-well plate respectively) BDNF (50 ng/ml, Sigma) was added
into each well and the plates were incubated for additional 3 days (total of
12 days from the initial induction).
5.4 Immunofluorescence staining
For assessing the differentiation process, three time points, 5, 9 and 12 days
in culture were used as checkpoints for indicative markers. The markers
for both staining and qPCR experiments were chosen for their known spe-
cific expressions in neuronal precursors, mature neurons and DA neurons
(Figure 5.2). The markers used in immunofluorescence experiments were
glial fibrillary acidic protein (GFAP) [2], nestin [194], neuron-specific eno-
lase (NSE/ENO2) [195] and tyrosine hydroxylase (TH) [196]. These markers
were followed at the time points 0, 5, 9 and 12 in the pilot experiment, the
0 time point kept as a reference (Fig. 5.3). In the material experiments,
Whole molecule control (WMC, Mouse IgG) was used as a negative control,
and the markers were stained at time points 5, 9 and 12 (Fig. 5.4).
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Figure 5.2: Immunofluorescence and qPCR markers expressed by the differ-
entiating neuronal cells. The strength of the color indicated the expected
strength of expression of the markers as the differentiation proceeds. The
time runs vertically from the top towards the bottom of the image.
For immunofluorescence staining, the plates were fixed with 4% paraform-
aldehyde (PFA) in PBS for 20 minutes at room temperature and washed 3 x
10 minutes with PBS. The cells were then permeabilized with 0.5% Triton X-
100/PBS solution for 10 minutes at RT and washed 3 x with PBS. Goat serum
was used to block the cells with a solution of 90% bovine serum albumin
(BSA) (0.1% in PBS) and 10% goat serum for 30 minutes.
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Figure 5.3: A timeline for the differentiation and immunofluorescence stain-
ing for hMSCs on glass coverslips as well as RT-qPCR for both the initial
experiment and material samples. The differentiation medium containing
NBM, B27, Shh, FGF8 and FGF2 was added at time point 0, followed by
the addition of BDNF at time point 9. The assessment was conducted using
immunofluorescence staining and RT-qPCR with markers GFAP, nestin, NSE
and TH, keeping the 0. time point as a reference (*).
Primary antibodies against GFAP (Anti-GFAP mAb, Abnova), nestin
(Anti-NES mAb, Abnova), NSE (Anti-NSE mAb, Abcam), Th (Anti-Th
mAb, Abcam) and WMC IgG (Mouse IgG, Whole Molecule Control, Thermo
Fisher Scientific) were diluted in PBS/BSA (0.1%) -solution. The dilutions
used for these experiments were 1:50 for GFAP, nestin and NSE and 1:20 for
TH and WMC. The samples were stained with 50 μl of primary antibody
solution for 1 h at RT and washed 3 x with PBS.
The secondary antibodies, Alexa FluorR© 488 (Goat anti-Mouse IgG,
Thermo Fisher Scientific) for the pilot hMSC experiment and Alexa FluorR©
568 (Goat anti-Mouse IgG, Thermo Fisher Scientific) for subsequent experi-
ments, were diluted 1:200 in PBS/BSA (0.1%) -solution and the samples were
incubated for another hour with 50 μl of this solution. After washing 3 x with
PBS/BSA (0.1%), the cells were fixed onto the microscope slides with Vec-
tashield Mounting Medium containing DAPI (4’,6-diamidino-2-phenylindole)
for staining the nuclei. The samples were imaged with a fluorescence micro-
scope (Olympus BX51M, camera Leica DFC420).
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Figure 5.4: A timeline for the differentiation and immunofluorescence stain-
ing of hMSCs on material samples. The differentiation medium containing
NBM, B27, Shh, FGF8 and FGF2 was added at time point 0, followed by the
addition of BDNF at time point 9. The markers for staining, GFAP, nestin,
NSE and TH were assessed at time points 5, 9 and 12, having WMC as a
negative control (*).
5.5 Quantitative real-time PCR
The four markers followed by immunofluorescence were further assessed by
qPCR: GFAP [197–199], nestin [197, 199], NSE [198] and Th [3] (see Fig. 5.3).
At four time points 0, 5, 9 and 12 days in culture, the medium was removed
from three replicates from the 12-well plate, the cells were lysed with RPE
lysis buffer and the total RNA extraction was conducted using RNeasy Mini
Kit (Qiagen Valencia, CA, USA) according to the manufacturer’s protocol.
The RNA obtained was counted and stored at -70◦C. In order to amplify
the RNA, complementary first-stand DNA (cDNA) synthesis was performed
from total RNA using Maxima First-Strand cDNA Synthesis Kit (Thermo
Fisher Scientific) according to the manufacturer’s protocol.
Four forward-reverse primer pairs were designed to further assess the ex-
pression of the neuronal markers GFAP, nestin, NSE and Th (Table 5.2).
The corresponding sequences for the markers were searched in the National
Center for Biotechnology Information (NCBI) Entrez search system, and the
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primers were designed using the Applied Biosystems Primer Express soft-
ware. The specificity was verified with the NCBI Primer-BLAST online tool
and the primers were produced by Oligomer (Helsinki, Finland). Commercial
RPLP0 and GAPDH primers were used as housekeeping genes.
Quantitative real-time qPCR was run for all cDNA samples using Step-
OnePlusTM Real-Time PCR System instrument. A master mix for each
gene was prepared from the following components: 12.5 μl Maxima SYBR
Green/ROX qPCR Master Mix (2X, Thermo Fisher Scientific), 8.5 μl Nuc-
lease-free water and 1 μl of both forward and reverse primers (concentration
5 μM). 2 μl of cDNA was added to 23 μl of the master mix. The real-time
qPCR programme consisted of an initial denaturation step for 3 min at 95◦C,
followed by 45 cycles of denaturation at 95◦C for 10s, annealing at 60◦C for
30s and extension at 72◦C for 30s. The programme was completed with
a melting step with ramping to 95◦C (0.5◦C/step). The The results were
analyzed using the relative quantitation method.
Table 5.2: Primers for assessing the hMSC differentiation with RT-qPCR
using GFAP, nestin, NSE and Th as markers. RPLP0 and GAPDH were
used as housekeeping genes. The NM codes, forward and reverse primer
sequences, melting temperatures (Tm) and amplicon lengths are listed for
each gene of interest.
Gene NM code Forward/Reverse Primer Tm(◦C) Amplicon
length (bp)
GFAP NM 001131019.2 CACCGCAGCCCTGAAAGA 59.97 55
GTTGCTGGACGCCATTGC 60.13
Nestin NM 006617.1 AGCCCTGACCACTCCAGTTTAG 61.68 128
CCCTCTATGGCTGTTTCTTTCTCT 60.08
NSE NM 001975.2 TTGCTCTTGTCCCACGTGTCT 61.91 62
CCCAGCACTATGCACAGTTCA 60.61
Th NM 000360.3 CCGAGCTGTGAAGGTGTTTGA 60.81 128
CGGGCCGGGTCTCTAGAT 60.20
RPLP0 NM 001002.3 GGCGACCTGGAAGTCCAACT 62.11 149
NM 053275.3 CCATCAGCACCACAGCCTTC 61.31
GAPDH NM 001975002046 AGTCAACGGATTTGGTCGTATTG 59.32 150
NM 001289746 TGGAATTTGCCATGGGTGGA 59.88
NM 001289745.1
6 Results and discussion
The differentiation process of the hMSCs was visualized by immunofluores-
cence and further analyzed using real-time quantitative PCR. These methods
were first tested by culturing C6 and PC12 cells and differentiating hMSCs
on glass coverslips. The immunofluorescence results from the first experi-
ments with C6 and PC12 cells are shown in Figures 6.1, 6.2 and with hMSCs
in 6.3. The stained cells from the material experiments with eight differ-
ent material types are presented in Figures 6.4-6.11. The amounts of RNA
extracted from the samples are listed in Tables 6.1 and 6.2 and the qPCR
relative quantification results are presented in Figures 6.13.
6.1 Immunofluorescence staining
The adequate functionality and specificity of the chosen antibodies were first
examined on cultured C6 and PC12 cells. In glial-like C6 cells, the expres-
sion of GFAP was strongly visible as expected, and also differed from the
control (Fig. 6.1). In contrast, the glial cell associated GFAP showed weaker
fluorescence in PC12 cells, which represent a neural cell line (Fig. 6.2). In
addition, also NSE showed lower expression than nestin and TH, but could
still be distinguished from the control WMC.
The first hMSC differentiation experiment was conducted only up to the
9. time point and was then stopped due to unexpected technical issues. How-
ever, the staining results were obtained from the 9. time point samples con-
firming the desired specificity of the antibodies (Fig. 6.3). However, it was
also seen that the differentiation had probably not been completed due to the
early interruption of the process, since both NSE and TH showed only weak
fluorescence. Nevertheless, these pilot experiments verified the applicability
of the GFAP, nestin, NSE and TH antibodies in assessing the differentiation
process of hMSCs.
The main experiment designed to study the differentiation of hMSCs on
several electrode materials was successfully completed, and the immunoflu-
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Figure 6.1: Immunofluorescence images of stained C6-cells. The nuclei are
shown in blue (DAPI) and the antibodies in red (AlexaFluor R© 568). The
left column shows stained nuclei, the middle one stained actin and the right
one the merged images for antibodies GFAP and negative control WMC IgG
(Whole Molecule Control IgG).
orescence data was obtained according to the research plan using four anti-
bodies GFAP, nestin, NSE and TH (see section 5.4). The results are shown
in Figures 6.4-6.11.
On ta-C surfaces with no coating or stimulation, the hMSCs show good
adherence, they are able to grow and proliferate and the material does not
seem to have any toxic effect on them (Fig. 6.4). There is also no evidence of
differentiation as would be expected due to the absence of any stimulation.
This is also the case with ta-C materials coated with PDL (Fig. 6.5). In
addition, it seems that there are no detectable differences between these two
sample types suggesting an indifference of hMSC behavior to PDL-coating.
This is somewhat surprising, since PDL and PLL (poly-L-lysine) are fre-
quently used in cell culture conditions to improve cell adherence onto the
surface. However, Qian et al. [200] obtained similar results by comparing
neuronal differentiation of hMSCs on different substrate coatings. It was
concluded that PDL was the only coating among the tested substrates that
did not support the growth and expansion of the hMSCs. Therefore, in the
future it might be beneficial to replace PDL with a coating that has shown
more positive effects on MSC growth and differentiation. For example, a sol-
uble basement membrane extract known as Matrigel has been seen to both
enhance the differentiation process in hMSCs as well as substantially improve
cell expansion [200].
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Figure 6.2: Immunofluorescence images of stained PC12-cells. The nuclei are
shown in blue (DAPI) and the antibodies in red (AlexaFluorR© 568). The left
column shows stained nuclei, the middle one stained actin and the right one
the merged images for each antibody GFAP, nestin, NSE, TH and negative
control WMC IgG (Whole Molecule Control IgG).
In contrast to the untreated samples, the stimulated cells grown on ta-C
exhibit distinctive morphology resembling neuronal shape both with and
without PDL-coating (Fig. 6.6 and 6.7)). Especially samples stained with
nestin antibody clearly show the elongated neurites in comparison with the
more random shape of the unstimulated cells.
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Figure 6.3: Immunofluorescence images of stained differentiating hMSC cells
with a) GFAP, b) nestin, c) NSE and d) TH (9. time point). The nuclei are
shown in blue (DAPI) and the antibodies in green (AlexaFluorR© 488).
In general, there seem to be less cells on the stimulated samples, which
would imply arrested proliferation and increased differentiation. This obser-
vation is also in agreement with another study that used hMSCs to generate
mature neurons [112]. Moreover, the DAPI-stained nuclei have obtained a
longer shape instead of the round ones observed in undifferentiated cells.
However, although the stimulated samples coated with PDL seem to ex-
press NSE at the 9. time point (Fig. 6.7), there is still no sign of TH expres-
sion on either of these material types, even at the 12. time point. In addition,
the nestin expression does not diminish towards the last time point as would
be expected if the cells were developing from progenitors into mature neu-
rons. It seems as though the differentiation is still in progress and not yet
fully completed, since some NSE is visible but TH is still to be developed.
In several studies inducing MSCs into DA neurons, the levels of TH have
been clearly elevated already at day 7 [110], 12 [3] or 14 [112] in culture.
However, in some protocols, the differentiation process has been prolonged
for 14-30 days for neurons [141, 198] or even 35-42 days to generate DA
neurons from rat MSCs [111]. Thus, it would be relevant to determine the
optimal timeline for differentiation from hMSCs by following the process over
a longer period of time and with regular checkpoints along the way.
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Figure 6.4: Immunofluorescence images of stained hMSCs on ta-C samples.
The nuclei are shown in blue (DAPI) and the antibodies in red (AlexaFluorR©
568). The left column shows stained nuclei, the middle one stained actin and
the right one the merged images for each antibody GFAP, nestin, NSE and
TH.
However, an extension in the differentiation protocol would also require
multiple markers and methods to assess them. In addition, longer incubation
periods would call for adjustments to the media volumes as well as replacing
the differentiation media in several occasions to avoid drying of the cells and
running out of nutrients.
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Figure 6.5: Immunofluorescence images of stained hMSCs on ta-C samples
coated with PDL. The nuclei are shown in blue (DAPI) and the antibodies
in red (AlexaFluorR© 568). The left column shows stained nuclei, the middle
one stained actin and the right one the merged images for each antibody
GFAP, nestin, NSE and TH.
A similar overall cell behavior to those cultured on ta-C materials can
also be observed in the cells grown on samples coated with carbon nanodia-
monds. While the hMSCs cultured on vox-coated samples do not show signs
of differentiation (Fig. 6.8), the morphological change in the stimulated cells
is apparent already at the 5. time point (Figs. 6.10 and 6.11). Further-
more, the expression of NSE follows the predicted pattern showing transient
increased levels at the 9. time point before decreasing again at the 12th.
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Figure 6.6: Immunofluorescence images of stained hMSCs on ta-C samples
stimulated with differentiation medium. The nuclei are shown in blue (DAPI)
and the antibodies in red (AlexaFluorR© 568). The left column shows stained
nuclei, the middle one stained actin and the right one the merged images for
each antibody GFAP, nestin, NSE and TH.
An interesting remark is that the morphology of the cells cultured on vox
surface seems to be shifted towards a neuron-like shape at the 12. time point
(Fig. 6.8). This is in agreement with the known effect of nanotopographical
cues on stimulating neurogenesis (see Section 3.3). The inducive effect is
even more elevated on the vox samples functionalized with BDNF (Fig. 6.9).
On these materials, there is also a slight NSE expression visible at the latest
time point, suggesting an effect of the linked BDNF on the cell behavior.
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Figure 6.7: Immunofluorescence images of stained hMSCs on ta-C samples
coated with PDL and stimulated with differentiation medium. The nuclei are
shown in blue (DAPI) and the antibodies in red (AlexaFluor R© 568). The
left column shows stained nuclei, the middle one stained actin and the right
one the merged images for each antibody GFAP, nestin, NSE and TH.
On the contrary, there are no significant differences in the cell behavior
between the stimulated samples, either on vox-surfaces or vox functionalized
with BDNF (Figs. 6.10 and 6.11). Nevertheless, coating ta-C samples with
carbon nanodiamonds seems to have beneficial effects on the differentiation
process. In addition, due to its multiple carboxyl sites, the vox-coating pro-
vides a useful platform for functionalization with various molecules such as
BDNF.
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Figure 6.8: Immunofluorescence images of stained hMSCs on vox samples.
The nuclei are shown in blue (DAPI) and the antibodies in red (AlexaFluorR©
568). The left column shows stained nuclei, the middle one stained actin and
the right one the merged images for each antibody GFAP, nestin, NSE and
TH.
A rather surprising result is the constant expression of nestin in virtu-
ally all samples. Nestin is expected to be expressed by neuronal stem cells
and developing neurons and gradually disappear as the cells maturate from
progenitors into neurons. Although the fluorescence is stronger from the
stimulated cells, it is also clearly seen in the untreated hMSCs.
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Figure 6.9: Immunofluorescence images of stained hMSCs on vox samples
functionalized with BDNF. The nuclei are shown in blue (DAPI) and the
antibodies in red (AlexaFluor R© 568). The left column shows stained nuclei,
the middle one stained actin and the right one the merged images for each
antibody GFAP, nestin, NSE and TH.
It could be argued that the persistent expression of nestin is simply due to
unspecific binding of the antibody, but when comparing the nestin expression
of the stimulated cells to the negative control of vox-samples (Fig. 6.12), this
explanation does not seem justified. Unexpectedly, the same observation
was also done in another study assessing the specification of hMSCs into
DA neurons [3]. In this study, further functional analysis of the stimulated
cells showed that they exhibited neuronal precursor -like excitable properties
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Figure 6.10: Immunofluorescence images of stained hMSCs on vox samples
stimulated with differentiation medium. The nuclei are shown in blue (DAPI)
and the antibodies in red (AlexaFluorR© 568). The left column shows stained
nuclei, the middle one stained actin and the right one the merged images for
each antibody GFAP, nestin, NSE and TH.
rather than those characteristic to mature neurons. This would support the
deduction that the cell maturation process is not yet completed.
On the other hand, other neuronal markers such as beta-tubulin III and
NeuN have also been seen to be expressed by several cell types, although
previously thought to be neuron-specific [11]. In addition, it has been seen
that different factors such as cell stress or disruption of the cytoskeleton can
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Figure 6.11: Immunofluorescence images of stained hMSCs on vox samples
stimulated with differentiation medium. The nuclei are shown in blue (DAPI)
and the antibodies in red (AlexaFluorR© 568). The left column shows stained
nuclei, the middle one stained actin and the right one the merged images for
each antibody GFAP, nestin, NSE and TH.
affect cell morphology and gene regulation [201]. Thus, it is not sufficient to
assess the differentiation by cellular markers alone, but also functional analy-
sis is required to evaluate the electrophysiological properties of the generated
cells.
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Figure 6.12: Immunofluorescence images of stained hMSCs on vox samples
stimulated with differentiation medium. The nuclei are shown in blue (DAPI)
and the antibodies in red (AlexaFluor R© 568). The samples are nestin (a)
and negative control (b).
6.2 Quantitative real-time PCR
The amounts of RNA (ng/μl) obtained from the samples of the pilot hMSC
experiment are shown in Table 6.1. From each of these samples, 39.2 ng RNA
was translated into cDNA and amplified with qPCR. The qPCR results are
shown in Figure 6.13. The results are presented as RQs (relative quantita-
tion), first standardized by subtracting the corresponding Ct values of the
housekeeping gene RPLP0 from the Cts of the sample and then normalized as
the fold expression with respect to those of the 0. time point (RQ = 1, shown
as a dashed line). The positive error bars represent the standard deviation
of the three replicates and are also identical to the negative side (not shown
for the clarity of the image). The RQs are calculated as the average of the
three replicates for the markers GFAP, nestin and NSE. The Ct values for
TH were either undetermined or above 30, making them unreliable.
Table 6.1: The amounts of RNA (ng/μl) from the cells cultured on PDL-
coated well plates at time points 0, 5, 9 and 12. Three replicates A, B and
C were obtained for each time point.
Material Time point
0. 5. 9. 12.
A B C A B C A B C A B C
PDL 2.9 8.7 16.6 14.3 28.0 17.6 4.4 25.1 28.1 3.1 2.9 2.8
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Figure 6.13: qPCR results from the first hMSC differentiation experiment.
Relative quantification of markers nestin, NSE and GFAP. Results are stan-
dardized and normalized as the fold expression with respect to those of the 0.
time point (RQ = 1, dashed line). The positive error bars show the standard
deviation of the three replicates and are identical to the negative side. RQs
are calculated as the average of three replicates.
According to these results, the expression of GFAP would be over four
times more at time point 9 than at time point 0, which is not the outcome
that was expected according to Figure 5.2. Similarly, the levels of NSE seem
to decrease rather than increase towards the later time points. In contrast,
nestin shows the correct profile with initial increase of expression followed by
a drop at the 12. time point. However, the Ct values for GFAP were slightly
above 30, which compromises the reliability of the results. It should also be
noticed that the amount of cDNA might not have been sufficient for accurate
qPCR amplification. Nevertheless, these first results provided an adequate
basis for the subsequent experiments with electrode materials.
The amounts of RNA (ng/μl) obtained from the material samples from
time points 0, 5, 9 and 12 are listed in Table 6.2. From these samples, 21 ng
of RNA was translated into cDNA and amplified with qPCR. The RQ values
from qPCR for each material type at all time points are presented in Figure
6.14. The RQs were calculated as described above.
On the ta-C samples, the stem cells were not under any stimulative influ-
ence, and thus would be expected to show low levels of neural markers and
possibly stronger signals from GFAP. Indeed, GFAP seems to increase to-
wards the 12. time point, although this is not definite due to the rather wide
error bars. Similarly, also nestin, NSE and TH behave as expected within
the error limits.
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Table 6.2: The amounts of RNA (ng/μl) from each material type at time
points 0, 5, 9 and 12. The sample materials were ta-C (1.), ta-C with stim-
ulation (2.), PDL-coated ta-C with stimulation (3.) and vox functionalized
with BDNF (4.). Three replicates A, B and C were obtained for each time
point.
Material Time point
0. 5. 9. 12.
A B C A B C A B C A B C
1. 9.7 5.7 6.6 10.0 6.3 7.0 10.5 3.9 6.7 13.7 3.3 4.8
2. 6.1 4.1 11.1 3.2 15.9 4.4 5.0 2.8 1.9 5.4 8.3 4.1
3. 18.3 11.7 12.2 2.3 3.0 1.5 6.6 2.7 3.7 4.3 2.6 2.5
4. 4.2 13.7 4.2 2.4 3.1 3.3 13.1 4.6 5.7 3.3 2.4 1.8
The stimulated cells on ta-C materials also show expected marker expres-
sions, although again with some large error bars. The expression of GFAP is
decreased towards the later time points, which is consistent with the neuron-
like morphology seen in the immunofluorescence staining. Moreover, the
levels of NSE increase at day 12, also suggesting a shift towards neuronal
differentiation. In contrast, as already observed from the staining results,
the expression of TH is very weak if not negligible.
The results from the ta-C coated with PDL and stimulated with differ-
entiation medium significantly differ from those without PDL-coating. The
most predominant variation is seen in the GFAP expression, which is highly
elevated on the PDL substrate, suggesting an increase in glial cell specifi-
cation. However, the other strongly expressed marker is NSE, associated
with neural lineage. The same observations can be seen from the vox BDNF
samples. While nestin shows relatively constant expression for both material
types, as was also seen in the fluorescence images, the unexpected burst of
expression of GFAP is highly contradictory to the previously hypothesized
expression profiles (see Fig. 5.2).
In general, the results from these qPCR experiments seem somewhat in-
consistent with the immunofluorescence images and the expectations based
on the known expression profiles of the markers (see Fig. 5.2). However,
some of the expression levels are accompanied by relatively wide error limits,
allowing several different interpretations of the expression profiles. The con-
sistency between the samples could be increased by transferring the material
samples into new wells before RNA extraction to ensure that the obtained
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Figure 6.14: qPCR results from the hMSC differentiation experiment on elec-
trode materials ta-C, ta-C with stimulation (ta-C stim), PDL-coated ta-C
with stimulation (ta-C PDL stim) and vox functionalized with BDNF (vox
BDNF). Relative quantification of markers GFAP, nestin, NSE and TH. Re-
sults are standardized and normalized as the fold expression with respect to
those of the 0. time point (RQ = 1, dashed line). The positive error bars
show the standard deviation of the three replicates and are identical to the
negative side. RQs are calculated as the average of three replicates.
RNA originates solely from the cells grown on the samples. In addition, the
size of the material samples greatly affects the amount of RNA isolated from
the cells. While the sample size of 1 cm x 1 cm has been proven appropriate
in osteogenesis of MSCs [202], it might not be sufficient for differentiating
MSCs into neurons. The size of the samples becomes a limiting factor due
to the reduced proliferation of the differentiating cells. Therefore, a bigger
sample size could be used in future studies to obtain more reliable data from
qPCR experiments.
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The next step in developing the optimal protocol for differentiating hMSCs
into DA neurons would be increasing the yield of cells expressing DA specific
markers, and most importantly, finding the means to generate electrically
functional neurons. Although hMSCs have already been successfully dif-
ferentiated into neuron-like cells in multiple experiments, the ability to fire
spontaneous or evoked action potentials from these cells is yet to be accom-
plished. It has been proven that cells expressing neuronal markers and even
readily secreting dopamine might still show impaired electrical functional-
ity in whole cell recordings [3]. Therefore, assessing these properties of the
generated cells is essential in evaluating their maturity and suitability for
medical applications.
7 Conclusions
In this thesis work, the process of adult stem cell differentiation into neurons
was studied via two approaches: a literature review on the field of adult
neurogenesis and an experimental assessment of a protocol for differentiating
hMSCs into DA neurons. The literature study covered the main cellular
pathways related to neuronal and DA differentiation in vivo as well as several
methods for guiding stem cell behavior in vitro. In addition, the recent
development in using stem cells and active materials in medical applications
was discussed.
The experimental part was carried out by culturing hMSCs under a dif-
ferentiation medium and following their development on several ta-C -based
material types via immunofluorescence staining and real-time qPCR. The ef-
fects of PDL-coating, carbon nanodiamond-coating and BDNF-functionaliza-
tion on the differentiation process were evaluated using cellular markers re-
lated to neurogenesis: GFAP, nestin, NSE and TH.
Several pilot studies were conducted previous to the main material expe-
riments. These initial studies with C6, PC12 and hMSC cells confirmed
the sufficient expression of the antibodies used in the immunofluorescence
staining as well as the functionality of the qPCR primers. In the main
experiment, the hMSCs were differentiated for 12 days in culture on four
different carbon-based materials.
The results from the immunofluorescence staining indicate that while the
stimulation medium seems to shift the fate of the hMSCs towards the neu-
ronal lineage on all material types, the process might not be fully completed
as suggested by the lack of TH expression. Moreover, nestin was visible on all
samples including the stimulated cells at the 12. time point. This was partly
explained by another study observing nestin expression from undifferenti-
ated hMSCs [3]. However, in the stimulated cells the persistent nestin levels
further imply that the differentiation process is still in progress at the time
point 12, thus raising a question of the adequate amount of time required for
complete maturation.
The qPCR results from the cells cultured or stimulated on ta-C showed
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expected expression profiles for all markers, although with relatively wide
error limits. On the stimulated ta-C samples, the elevated NSE levels at the
last time point were in agreement with the staining results, corresponding to
the slight detected fluorescence and neuron-like morphology of the cells seen
from the images. On the contrary, the marker profiles from ta-C coated with
PDL revealed an undesirable effect of the PDL-coating. The highly increased
GFAP-levels indicated a presence of glial-like cells rather than neurons.
A similar effect was also seen from the cells grown on the vox BDNF
materials, although these also expressed the neuron-specific NSE. From the
combined results of the stainings and qPCR, it could be deduced that the
nanotopography of the substrate seems to guide the hMSCs towards the
neuronal lineage, and this effect could be further enhanced by the BDNF
functionalization. However, a general problem in the qPCR experiments was
found to be the insufficient amount of RNA obtained from the samples. This
was most likely due to the small sample size combined with a differentiation-
related decrease in the amount of cells per sample. Thus, bigger samples
would be necessary in order to obtain more reliable qPCR results from neu-
rogenesis experiments with hMSCs.
For future experiments, it will be important to strive for improving the
efficacy of the hMSC differentiation protocol to gain higher yields of mature
DA neurons from the stem cells. This could be achieved by optimizing the
timeline for the differentiation process, as well as combining the chemical
stimulation with nanotopographical cues to potentially enhance the commit-
ment of the stem cells towards the neuronal lineage. Another essential goal
is the successful generation of electrically functional neurons and the use of
proper assessment methods to confirm the capability of the cells to fire action
potentials.
The developments in the research on neurogenesis in the adult brain pave
the way for deeper understanding of the mechanisms governing the fate of
the stem cells in vivo and thus enable the breakthroughs in the stem cell
experiments conducted in cell laboratories. In applications such as active
neural scaffolds and closed-loop neurostimulation, a variety of questions re-
main unsolved, especially related to the tissue response and biocompatibility
of the implants. The use of stem cells to replace damaged neural tissue or
nanostructured surfaces to guide the regrowth of neurites could offer new
approaches in tackling these challenges, potentially enabling new strategies
in treating incurable neurodegenerative diseases.
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